1
|
Epaillard N, Lusque A, Jacot W, Mailliez A, Bachelot T, Arnedos M, Le Du F, Brain E, Ferrero JM, Massard V, Desmoulins I, Mouret-Reynier MA, Levy C, Gonçalves A, Leheurteur M, Petit T, Filleron T, Bosquet L, Pistilli B, Frenel JS. Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort. ESMO Open 2024; 9:103447. [PMID: 38703431 PMCID: PMC11087908 DOI: 10.1016/j.esmoop.2024.103447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Revised: 03/27/2024] [Accepted: 04/08/2024] [Indexed: 05/06/2024] Open
Abstract
BACKGROUND Breast cancer (BC) is the second most common cancer that metastasizes to the brain. Particularly up to half of patients with human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (mBC) may develop brain metastases over the course of the disease. Nevertheless, little is known about the prevalence and the outcome of brain and leptomeningeal metastases (BLMM) in HER2-low BC. We compared the cumulative incidence of BLMM and associated outcomes among patients with HER2-low, HER2-negative (HER2-) and HER2+ mBC. PATIENTS AND METHODS This cohort study was conducted from the Epidemiological Strategy and Medical Economics (ESME) mBC database and included patients treated for mBC between 2012 and 2020 across 18 French comprehensive cancer centers and with known HER2 and hormone receptor (HR) status. The cumulative incidence of BLMM after metastatic diagnosis was estimated using a competing risk methodology with death defined as a competing event. RESULTS 19 585 patients were included with 6118 (31.2%), 9943 (50.8%) and 3524 (18.0%) being HER2-low, HER2- and HER2+ mBC, respectively. After a median follow-up of 48.6 months [95% confidence interval (CI) 47.7-49.3 months], BLMM were reported in 4727 patients: 1192 (25.2%) were diagnosed with BLMM at first metastatic diagnosis and 3535 (74.8%) after metastatic diagnosis. Multivariable analysis adjusted for age, histological grade, metastases-free interval and HR status showed that the risk of BLMM at metastatic diagnosis was similar in patients with HER2- compared to HER2-low mBC [odds ratio (OR) (95% CI) 1.00 (0.86-1.17)] and higher in those with HER2+ compared to HER2-low [OR (95% CI) 2.23 (1.87-2.66)]. Similar results were found after metastatic diagnosis; the risk of BLMM was similar in HER2- compared to HER2-low [subdistribution hazard ratio (sHR) (95% CI) 1.07 (0.98-1.16)] and higher in the HER2+ group [sHR (95% CI) 1.56 (1.41-1.73)]. CONCLUSIONS The prevalence and evolution of BLMM in HER2-low mBC are similar to those in patients with HER2- tumors. In contrast to patients with HER2+ mBC, the prognosis of BLMM remains dismal in this population.
Collapse
Affiliation(s)
- N Epaillard
- Department of Medical Oncology, Gustave Roussy, Villejuif.
| | - A Lusque
- Biostatistics & Health Data Science Unit, Institut Claudius Regaud, IUCT Oncopole, Toulouse
| | - W Jacot
- Department of Medical Oncology, Institut régional du Cancer, Montpellier
| | - A Mailliez
- Department of Medical Oncology, Centre Oscar Lambret, Lille
| | - T Bachelot
- Department of Medical Oncology, Centre Léon Bérard, Lyon
| | - M Arnedos
- Department of Medical Oncology, Institut Bergonié, Bordeaux
| | - F Le Du
- Department of Medical Oncology, Centre Eugène Marquis, Rennes
| | - E Brain
- Department of Medical Oncology, Institut Curie, Saint-Cloud
| | - J M Ferrero
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice
| | - V Massard
- Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy
| | - I Desmoulins
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon
| | | | - C Levy
- Department of Medical Oncology, Centre François Baclesse, Caen
| | - A Gonçalves
- Department of Medical Oncology, Institut Paoli Calmette, Marseille
| | - M Leheurteur
- Department of Medical Oncology, Centre Henri Becquerel, Rouen
| | - T Petit
- Department of Medical Oncology, Centre Paul Strauss ICANS, Strasbourg
| | - T Filleron
- Biostatistics & Health Data Science Unit, Institut Claudius Regaud, IUCT Oncopole, Toulouse
| | - L Bosquet
- Health Data and Partnership Department, Unicancer, Paris
| | - B Pistilli
- Department of Medical Oncology, Gustave Roussy, Villejuif; INSERM U1279, Gustave Roussy, Villejuif
| | - J S Frenel
- Department of Medical Oncology, Institut de Cancerologie de L'Ouest, Saint-Herblain, France
| |
Collapse
|
2
|
Frenel JS, Zeghondy J, Guérin-Charbonnel C, Mailliez A, Volant E, Poumeaud F, Patsouris A, Arnedos M, Bailleux C, Cabal J, Galland L, de Nonneville A, Guiu S, Dalenc F, Pistilli B, Bachelot T, Pierga JY, Le Du F, Bocquet F, Larrouquere L, Loirat D. Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer. JAMA Netw Open 2024; 7:e244435. [PMID: 38568692 PMCID: PMC10993071 DOI: 10.1001/jamanetworkopen.2024.4435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Accepted: 02/01/2024] [Indexed: 04/05/2024] Open
Abstract
Importance Little is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzumab-deruxtecan exposure among patients with ERBB2 (previously HER2)-positive metastatic breast cancer (MBC). Objective To investigate outcomes following TTC treatment in patients with ERBB2-positive MBC who had previously received trastuzumab-deruxtecan. Design, Setting, and Participants This cohort study included all patients with MBC who were treated in 12 French comprehensive cancer centers between August 1, 2020, and December 31, 2022. Exposure Tucatinib combined with trastuzumab and capecitabine administered at the recommended dose. Main Outcomes and Measures Clinical end points included progression-free survival (PFS), time to next treatment (TTNT), overall survival (OS), and overall response rate (ORR). Results A total of 101 patients with MBC were included (median age, 56 [range, 31-85] years). The median number of prior treatment lines for metastatic disease at TTC treatment initiation was 4 (range, 2-15), including 82 patients (81.2%) with previous trastuzumab and/or pertuzumab and 94 (93.1%) with previous ado-trastuzumab-emtansine) exposure. The median duration of trastuzumab-deruxtecan treatment was 8.9 (range, 1.4-25.8) months, and 82 patients (81.2%) had disease progression during trastuzumab-deruxtecan treatment, whereas 18 (17.8%) had stopped trastuzumab-deruxtecan for toxic effects and 1 (1.0%) for other reasons. Tucatinib combined with trastuzumab and capecitabine was provided as a third- or fourth-line treatment in 37 patients (36.6%) and was the immediate treatment after trastuzumab-deruxtecan in 86 (85.1%). With a median follow-up of 11.6 (95% CI, 10.5-13.4) months, 76 of 101 patients (75.2%) stopped TTC treatment due to disease progression. The median PFS was 4.7 (95% CI, 3.9-5.6) months; median TTNT, 5.2 (95% CI, 4.5-7.0) months; and median OS, 13.4 (95% CI, 11.1 to not reached [NR]) months. Patients who received TTC immediately after trastuzumab-deruxtecan had a median PFS of 5.0 (95% CI, 4.2-6.0) months; median TTNT of 5.5 (95% CI, 4.8-7.2) months, and median OS of 13.4 (95% CI, 11.9-NR) months. Those who received TTC due to trastuzumab-deruxtecan toxicity-related discontinuation had a median PFS of 7.3 (95% CI, 3.0-NR) months. Best ORR was 29 of 89 patients (32.6%). Sixteen patients with active brain metastasis had a median PFS of 4.7 (95% CI, 3.0-7.3) months, median TTNT of 5.6 (95% CI, 4.4 to NR), and median OS of 12.4 (95% CI, 8.3-NR) months. Conclusions and Relevance In this study, TTC therapy was associated with clinically meaningful outcomes in patients with ERBB2-positive MBC after previous trastuzumab-deruxtecan treatment, including those with brain metastases. Prospective data on optimal drug sequencing in this rapidly changing therapeutic landscape are needed.
Collapse
Affiliation(s)
- Jean-Sebastien Frenel
- Department of Medical Oncology, Institut de Cancerologie de l’Ouest, Saint-Herblain, France
| | - Jean Zeghondy
- Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France
| | | | - Audrey Mailliez
- Department of Medical Oncology, Oscar Lambret Comprehensive Cancer Center, Lille, France
| | - Elsa Volant
- Department of Medical Oncology, Institut de Cancerologie de l’Ouest, Saint-Herblain, France
| | | | - Anne Patsouris
- Department of Medical Oncology, Institut de Cancerologie de l’Ouest, Angers, France
| | - Monica Arnedos
- Department of Medical Oncology Bordeaux, Institut Bergonie, Bordeaux, France
| | - Caroline Bailleux
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
| | - Julie Cabal
- Department of Medical Oncology, Centre Eugene Marquis, Rennes, France
| | - Loick Galland
- Department of Medical Oncology, Centre Georges Francois Leclerc, Dijon, France
| | | | - Séverine Guiu
- Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France
| | | | - Barbara Pistilli
- Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France
| | - Thomas Bachelot
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France
| | | | - Fanny Le Du
- Department of Medical Oncology, Centre Eugene Marquis, Rennes, France
| | - François Bocquet
- Data Factory, Institut de Cancerologie de l’Ouest, Saint-Herblain, France
| | | | - Delphine Loirat
- Department of Medical Oncology, Institut Curie, Paris, France
| |
Collapse
|
3
|
Vanacker H, Treilleux I, Schiffler C, Bieche I, Campone M, Patsouris A, Arnedos M, Cottu PH, Jacquin JP, Dalenc F, Pinton A, Servant N, Attignon V, Rouleau E, Morel A, Legrand F, Jimenez M, Andre F, Bachelot T. p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. Br J Cancer 2024; 130:613-619. [PMID: 38182687 PMCID: PMC10876520 DOI: 10.1038/s41416-023-02549-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Revised: 11/27/2023] [Accepted: 12/11/2023] [Indexed: 01/07/2024] Open
Abstract
BACKGROUND To identify patients most likely to respond to everolimus, a mammalian target of rapamycin (mTOR) inhibitor, a prospective biomarker study was conducted in hormone receptor-positive endocrine-resistant metastatic breast cancer patients treated with exemestane-everolimus therapy. METHODS Metastatic tumor biopsies were processed for immunohistochemical staining (p4EBP1, PTEN, pAKT, LKB1, and pS6K). ESR1, PIK3CA and AKT1 gene mutations were detected by NGS. The primary endpoint was the association between the p4EBP1 expression and clinical benefit rate (CBR) at 6 months of everolimus plus exemestane treatment. RESULTS Of 150 patients included, 107 were evaluable for the primary endpoint. p4EBP1 staining above the median (Allred score ≥6) was associated with a higher CBR at 6 months (62% versus 40% in high-p4EBP1 versus low-p4EBP1, χ2 test, p = 0.026) and a longer progression-free survival (PFS) (median PFS of 9.2 versus 5.8 months in high-p4EBP1 versus low-p4EBP1; p = 0.02). When tested with other biomarkers, only p4EBP1 remained a significant predictive marker of PFS in multivariate analysis (hazard ratio, 0.591; p = 0.01). CONCLUSIONS This study identified a subset of patients with hormone receptor-positive endocrine-resistant metastatic breast cancer and poor outcome who would derive less benefit from everolimus and exemestane. p4EBP1 may be a useful predictive biomarker in routine clinical practice. CLINICAL TRIAL REGISTRATION NCT02444390.
Collapse
Affiliation(s)
| | | | | | | | - Mario Campone
- Institut de cancérologie de l'ouest Pays de Loire Nantes-Angers, Saint-Herblain, France
| | - Anne Patsouris
- Institut de cancérologie de l'ouest Pays de Loire Nantes-Angers, Saint-Herblain, France
| | | | | | | | - Florence Dalenc
- ICR, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, France
| | | | | | | | | | - Alain Morel
- Institut de cancérologie de l'ouest Pays de Loire Nantes-Angers, Saint-Herblain, France
- Univ Angers, Nantes Université, Inserm, CNRS, CRCI2NA, SFR ICAT, F-49000, Angers, France
| | | | | | | | | |
Collapse
|
4
|
Rhanine Y, Bonnefoi H, Goncalves A, Debled M, Le Moulec S, Bonichon N, Macgrogan G, Arnedos M, Dubroca-Dehez B, Grellety T. Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data. Breast 2024; 73:103667. [PMID: 38160476 PMCID: PMC10792951 DOI: 10.1016/j.breast.2023.103667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Revised: 12/20/2023] [Accepted: 12/21/2023] [Indexed: 01/03/2024] Open
Abstract
Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life. The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic AR + TNBC are in line with data from published trials.
Collapse
Affiliation(s)
- Yasmine Rhanine
- Medical Oncology Department, Institut Bergonié, Bordeaux, France
| | - Hervé Bonnefoi
- Medical Oncology Department, Institut Bergonié and Université de Bordeaux, UFR Sciences Médicales, Bordeaux, France
| | - Anthony Goncalves
- Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France
| | - Marc Debled
- Medical Oncology Department, Institut Bergonié, Bordeaux, France
| | | | | | | | - Monica Arnedos
- Medical Oncology Department, Institut Bergonié, Bordeaux, France
| | | | - Thomas Grellety
- Medical Oncology Department, Centre Hospitalier de la Côte Basque, Bayonne, France.
| |
Collapse
|
5
|
Galvin A, Courtinard C, Bouteiller F, Gourgou S, Dalenc F, Jacot W, Arnedos M, Bailleux C, Dieras V, Petit T, Emile G, Dubray-Longeras P, Frenel JS, Bachelot T, Mailliez A, Brain E, Desmoulins I, Massard V, Patsouris A, Goncalves A, Grinda T, Delaloge S, Bellera C. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort. Eur J Cancer 2024; 196:113422. [PMID: 37977105 DOI: 10.1016/j.ejca.2023.113422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Accepted: 10/31/2023] [Indexed: 11/19/2023]
Abstract
AIM To describe first-line treatment patterns, overall survival (OS) and real-world progression-free survival (rwPFS) in young women (<40) with metastatic breast cancer (mBC), as compared to women aged 40-69. MATERIALS AND METHODS Data on adult women diagnosed with mBC (2008-2017) were extracted from the ESME mBC database (NCT03275311) which includes consecutive patients starting first-line metastatic treatment in one of the 18 French Comprehensive cancer centers. We reported first-line therapeutic strategy and prognostic factors of OS and rwPFS for women aged < 40 and 40-69. RESULTS In total, 14,897 mBC women were included (1512 aged <40). HR+ /HER2- mBC was the most frequent subtype. First-line treatment differed between young patients and older ones for HR+ /HER2- and Triple Negative (TN) mBC. Median OS for women aged < 40 and 40-69, respectively, was 46.9 and 46.2 months for HR+ /HER2- mBC; 13.5 and 15.2 for TN mBC; and, 60.7 and 55.1 for HER2 + mBC. Median rwPFS under first line treatment was 11.6 and 11.9 months for HR+ /HER2- in women aged < 40 and 40-69, respectively; 5.5 and 5.9 for TN, and, 13.3 and 12.9 for HER2 + . Factors associated with shorter OS and rwPFS were similar for both women aged < 40 and 40-69 and included ≥ 3 metastatic sites, visceral metastases, and longer MFI, with time-varying effects observed for several prognostic factors. CONCLUSION Young women presented more frequently with TN and HER2 + subtypes and aggressive mBC than women aged 40-69 did. Prognostic factors of OS and rwPFS were quite similar between age groups and mBC subtypes.
Collapse
Affiliation(s)
- Angéline Galvin
- University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, 33000 Bordeaux, France.
| | - Coralie Courtinard
- University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, 33000 Bordeaux, France; Unicancer, Data and Partnership Department, 101 Rue de Tolbiac, 75654 Paris, France
| | - Fanny Bouteiller
- Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, 33000 Bordeaux, France
| | - Sophie Gourgou
- Biometrics unit, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298 Montpellier, France; University of Montpellier, 34000 Montpellier, France
| | - Florence Dalenc
- Department of Medical Oncology, Oncopole Claudius Regaud - IUCT, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France
| | - William Jacot
- Department of Medical Oncology, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298 Montpellier, France
| | - Monica Arnedos
- Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France
| | - Caroline Bailleux
- Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189 Nice, France
| | - Véronique Dieras
- Department of Medical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France
| | - Thierry Petit
- Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000 Strasbourg, France
| | - George Emile
- Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000 Caen, France
| | - Pascale Dubray-Longeras
- Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont Ferrand, France
| | - Jean-Sébastien Frenel
- Department of Medical Oncology, Institut de Cancérologie de Lorraine, Boulevard Jacques Monod, 44805 Nantes, France
| | - Thomas Bachelot
- Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008 Lyon, France
| | - Audrey Mailliez
- Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France
| | - Etienne Brain
- Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris, France
| | - Isabelle Desmoulins
- Department of Medical Oncology, Centre Georges-François Leclerc, 21079 Dijon, France
| | - Vincent Massard
- Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France
| | - Anne Patsouris
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Paul Papin, 15 rue André Boquel, 49055 Angers, France
| | - Anthony Goncalves
- Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009 Marseille, France
| | - Thomas Grinda
- Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France
| | - Suzette Delaloge
- Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France
| | - Carine Bellera
- University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, 33000 Bordeaux, France; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, 33000 Bordeaux, France
| |
Collapse
|
6
|
Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JÁ, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol 2023; 34:885-898. [PMID: 37597578 DOI: 10.1016/j.annonc.2023.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 08/03/2023] [Accepted: 08/08/2023] [Indexed: 08/21/2023] Open
Abstract
BACKGROUND HER2 mutations are targetable alterations in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients with HER2-mutant MBC received neratinib monotherapy, neratinib + fulvestrant, or neratinib + fulvestrant + trastuzumab (N + F + T). We report results from 71 patients with HR+, HER2-mutant MBC, including 21 (seven in each arm) from a randomized substudy of fulvestrant versus fulvestrant + trastuzumab (F + T) versus N + F + T. PATIENTS AND METHODS Patients with HR+ HER2-negative MBC with activating HER2 mutation(s) and prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy received N + F + T (oral neratinib 240 mg/day with loperamide prophylaxis, intramuscular fulvestrant 500 mg on days 1, 15, and 29 of cycle 1 then q4w, intravenous trastuzumab 8 mg/kg then 6 mg/kg q3w) or F + T or fulvestrant alone. Those whose disease progressed on F + T or fulvestrant could cross-over to N + F + T. Efficacy endpoints included investigator-assessed objective response rate (ORR), clinical benefit rate (RECIST v1.1), duration of response, and progression-free survival (PFS). Plasma and/or formalin-fixed paraffin-embedded tissue samples were collected at baseline; plasma was collected during and at end of treatment. Extracted DNA was analyzed by next-generation sequencing. RESULTS ORR for 57 N + F + T-treated patients was 39% [95% confidence interval (CI) 26% to 52%); median PFS was 8.3 months (95% CI 6.0-15.1 months). No responses occurred in fulvestrant- or F + T-treated patients; responses in patients crossing over to N + F + T supported the requirement for neratinib in the triplet. Responses were observed in patients with ductal and lobular histology, 1 or ≥1 HER2 mutations, and co-occurring HER3 mutations. Longitudinal circulating tumor DNA sequencing revealed acquisition of additional HER2 alterations, and mutations in genes including PIK3CA, enabling further precision targeting and possible re-response. CONCLUSIONS The benefit of N + F + T for HR+ HER2-mutant MBC after progression on CDK4/6is is clinically meaningful and, based on this study, N + F + T has been included in the National Comprehensive Cancer Network treatment guidelines. SUMMIT has improved our understanding of the translational implications of targeting HER2 mutations with neratinib-based therapy.
Collapse
Affiliation(s)
- K Jhaveri
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York.
| | - L D Eli
- Clinical Development, Puma Biotechnology, Los Angeles, USA
| | - H Wildiers
- University Hospitals Leuven, Leuven, Belgium
| | - S A Hurvitz
- David Geffen School of Medicine, UCLA, Los Angeles, Santa Monica, USA
| | - A Guerrero-Zotano
- Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain
| | - N Unni
- UT Southwestern Medical Center, Dallas
| | - A Brufsky
- Magee-Womens Hospital of UPMC, Pittsburgh
| | - H Park
- Washington University School of Medicine, St. Louis
| | - J Waisman
- City of Hope Comprehensive Cancer Center, Duarte
| | - E S Yang
- University of Alabama at Birmingham, Birmingham, USA
| | - I Spanggaard
- Department of Oncology, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - S Reid
- Division of Hematology/Oncology (Breast Oncology), The Vanderbilt-Ingram Cancer Center, Nashville
| | - M E Burkard
- Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison
| | - S Vinayak
- Seattle Cancer Care Alliance, Seattle, USA
| | - A Prat
- Hospital Clínic de Barcelona, Barcelona, Spain
| | - M Arnedos
- Department of Medical Oncology, Gustave Roussy, Villejuif
| | - F-C Bidard
- Department of Medical Oncology, UVSQ/Paris-Saclay University, Institut Curie, Saint Cloud, France
| | - S Loi
- Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne; The Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Australia
| | - J Crown
- St. Vincent's University Hospital, Dublin, Ireland
| | - M Bhave
- Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta
| | - S A Piha-Paul
- Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston
| | - J M Suga
- Kaiser Permanente, Department of Medical Oncology, Vallejo, USA
| | - S Chia
- Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
| | - C Saura
- Medical Oncology Service, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona
| | - J Á Garcia-Saenz
- Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), CIBERONC, Madrid
| | - V Gambardella
- Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia
| | - M J de Miguel
- START Madrid - Hospital Universitario Madrid Sanchinarro, Madrid, Spain
| | - E N Gal-Yam
- Institute of Breast Oncology, Sheba Medical Center, Ramat Gan
| | - A Rapael
- Sourasky Medical Center, Tel Aviv
| | - S M Stemmer
- Davidoff Cancer Center, Rabin Medical Center, Petah Tikva; Tel Aviv University, Tel Aviv, Israel
| | - C Ma
- Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis
| | - A B Hanker
- UT Southwestern Simmons Comprehensive Cancer Center, Dallas
| | - D Ye
- UT Southwestern Simmons Comprehensive Cancer Center, Dallas
| | | | - R Bose
- Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis
| | - L Peterson
- Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis
| | | | - A Frazier
- Clinical Development, Puma Biotechnology, Los Angeles, USA
| | - D DiPrimeo
- Clinical Development, Puma Biotechnology, Los Angeles, USA
| | - A Wong
- Clinical Development, Puma Biotechnology, Los Angeles, USA
| | - C L Arteaga
- UT Southwestern Simmons Comprehensive Cancer Center, Dallas
| | - D B Solit
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
| |
Collapse
|
7
|
Grinda T, Antoine A, Jacot W, Cottu PH, de la Motte Rouge T, Frenel JS, Mailliez A, Dalenc F, Goncalves A, Clatot F, Mouret Reynier MA, Levy C, Ferrero JM, Desmoulins I, Uwer L, Petit T, Jouannaud C, Arnedos M, Chevrot M, Courtinard C, Tredan O, Brain E, Pérol D, Pistilli B, Delaloge S. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. Eur J Cancer 2023; 189:112935. [PMID: 37385070 DOI: 10.1016/j.ejca.2023.05.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 05/30/2023] [Accepted: 05/31/2023] [Indexed: 07/01/2023]
Abstract
BACKGROUND Early metastatic relapse of triple-negative breast cancer (mTNBC) after anthracyclins and/or taxanes based (A/T) primary treatment represents a highly aggressive cancer situation requiring urgent characterisation and handling. Epidemio-Strategy-Medico-Economical-Metastatic Breast Cancer (ESME-MBC) database, a multicenter, national, observational cohort (NCT03275311) provides recent data on this entity. METHODS All ESME patients diagnosed between 2008 and 2020 with mTNBC occurring as a relapse after a systemic neoadjuvant/adjuvant taxane and/or anthracycline-based chemotherapy were included. Early relapses were defined by a metastatic diagnosis up to 12 months of the end of neo/adjuvant A/T chemotherapy. We assessed overall survival (OS) and progression-free-survival under first-line treatment (PFS1) by early versus late relapse (≥12 months). RESULTS Patients with early relapse (N = 881, 46%) were younger and had a larger tumour burden at primary diagnosis than those with late relapses (N = 1045). Early relapse rates appeared stable over time. Median OS was 10.1 months (95% CI 9.3-10.9) in patients with early relapse versus 17.1 months (95% CI 15.7-18.2) in those with late relapse (adjusted hazard-ratio (aHR): 1.92 (95% CI 1.73-2.13); p < 0.001). The median PFS1 was respectively 3.1 months (95% CI 2.9-3.4) and 5.3 months (95% CI 5.1-5.8); (aHR: 1.66; [95% CI 1.50-1.83]; p < 0.001). Among early relapsed patients, a higher number of metastatic sites, visceral disease but not treatment types, were independently associated with a poorer OS. CONCLUSION These real-world data provide strong evidence on the dismal prognosis, higher treatment resistance and major unmet medical need associated with early relapsed mTNBC. Database registration: clinicaltrials.gov Identifier NCT032753.
Collapse
Affiliation(s)
- Thomas Grinda
- Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France; Sorbonne University, Medicine, 21 rue de l'École de médecine, 75006 Paris, France.
| | - Alison Antoine
- Department of Biostatistics, DRCI, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France
| | - William Jacot
- Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM U1194, 208 Rue des Apothicaires, 34298 Montpellier, France
| | - Paul-Henri Cottu
- Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris & Saint-Cloud, France
| | - Thibault de la Motte Rouge
- Department of Medical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France
| | - Jean-Sébastien Frenel
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest Pays de Loire, 15 rue André Boquel, 49055 Angers, France
| | - Audrey Mailliez
- Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France
| | - Florence Dalenc
- Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France
| | - Anthony Goncalves
- Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009 Marseille, France
| | - Florian Clatot
- Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000 Rouen, France
| | - Marie-Ange Mouret Reynier
- Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont Ferrand, France
| | - Christelle Levy
- Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000 Caen, France
| | - Jean-Marc Ferrero
- Department of Medical Oncology, Centre Antoine Lacassagne, 06000 Nice, France
| | - Isabelle Desmoulins
- Department of Medical Oncology, Institut de Cancérologie de Bourgogne, 21079 Dijon, France
| | - Lionel Uwer
- Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France
| | - Thierry Petit
- Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000 Strasbourg, France
| | - Christelle Jouannaud
- Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100 Reims, France
| | - Monica Arnedos
- Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France
| | - Michaël Chevrot
- Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654 Paris, France
| | - Coralie Courtinard
- Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654 Paris, France; University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, 33000 Bordeaux, France
| | - Olivier Tredan
- Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008 Lyon, France
| | - Etienne Brain
- Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris & Saint-Cloud, France
| | - David Pérol
- Department of Biostatistics, DRCI, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France
| | - Barbara Pistilli
- Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France
| | - Suzette Delaloge
- Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France
| |
Collapse
|
8
|
Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V. Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer. Nat Commun 2022; 13:6928. [PMID: 36376284 PMCID: PMC9663725 DOI: 10.1038/s41467-022-34580-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Marta Palafox
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Laia Monserrat
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Meritxell Bellet
- Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain
| | - Guillermo Villacampa
- Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Abel Gonzalez-Perez
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain
- Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain
| | - Mafalda Oliveira
- Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain
| | - Fara Brasó-Maristany
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
| | - Nusaibah Ibrahimi
- Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France
- Oncostat U1018, Inserm, University Paris-Saclay, Villejuif, France
| | | | - Leonardo Mina
- Medica Scientia Innovation Research (MedSIR), Barcelona, Spain
| | | | - Andreu Òdena
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Mònica Sánchez-Guixé
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Marta Capelán
- Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain
| | - Analía Azaro
- Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain
| | - Alejandra Bruna
- Preclinical Modelling of Pediatric Cancer Evolution Group, The Institute of Cancer Research, London, UK
| | - Olga Rodríguez
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Marta Guzmán
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Judit Grueso
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Cristina Viaplana
- Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Javier Hernández
- Translational Molecular Pathology, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain
| | - Faye Su
- Novartis Pharmaceuticals, East Hanover, NJ, USA
| | - Kui Lin
- Genentech, Inc., South San Francisco, California, USA
| | - Robert B Clarke
- Breast Biology Group, Manchester Breast Centre, Manchester, UK
| | | | - Joaquín Arribas
- CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - Stefan Michiels
- Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France
- Oncostat U1018, Inserm, University Paris-Saclay, Villejuif, France
| | | | | | - Aleix Prat
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
- University of Barcelona, Barcelona, Spain
- Department of Medical Oncology, Hospital Clinic, Barcelona, Spain
- SOLTI Breast Cancer Research Group, Barcelona, Spain
- Department of Oncology, IOB Institute of Oncology, Barcelona, Spain
| | - Paolo Nuciforo
- Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Rodrigo Dienstmann
- Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Chandra S Verma
- Bioinformatics Institute (A*STAR), Singapore, Singapore
- School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
- Department of Biological Sciences, National University of Singapore, Singapore, Singapore
| | - Nuria Lopez-Bigas
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain
- Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - Maurizio Scaltriti
- Departments of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - Monica Arnedos
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
- Inserm Unit U981, Villejuif, France
| | - Cristina Saura
- Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain
| | - Violeta Serra
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
- CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
| |
Collapse
|
9
|
Geyer C, Garber J, Gelber R, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong A, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek S, Eisen A, Elsafy F, Fein L, Fielding A, Ford J, Friedman S, Gelmon K, Gianni L, Gnant M, Hollingsworth S, Im SA, Jager A, Jóhannsson Ó, Lakhani S, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas P, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer C, Španić T, Stickeler E, Toi M, Traina T, Viale G, Zoppoli G, Park Y, Yerushalmi R, Yang H, Pang D, Jung K, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke G, Sun Q, Parton M, Colleoni M, Schmidt M, Brufsky A, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt A. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. Ann Oncol 2022; 33:1250-1268. [PMID: 36228963 DOI: 10.1016/j.annonc.2022.09.159] [Citation(s) in RCA: 115] [Impact Index Per Article: 57.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Accepted: 09/22/2022] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer (EBC). The first pre-specified interim analysis (IA) previously demonstrated statistically significant improvement in invasive disease-free survival (IDFS) and distant disease-free survival (DDFS). The olaparib group had fewer deaths than the placebo group, but the difference did not reach statistical significance for overall survival (OS). We now report the pre-specified second IA of OS with updates of IDFS, DDFS, and safety. PATIENTS AND METHODS One thousand eight hundred and thirty-six patients were randomly assigned to olaparib or placebo following (neo)adjuvant chemotherapy, surgery, and radiation therapy if indicated. Endocrine therapy was given concurrently with study medication for hormone receptor-positive cancers. Statistical significance for OS at this IA required P < 0.015. RESULTS With a median follow-up of 3.5 years, the second IA of OS demonstrated significant improvement in the olaparib group relative to the placebo group [hazard ratio 0.68; 98.5% confidence interval (CI) 0.47-0.97; P = 0.009]. Four-year OS was 89.8% in the olaparib group and 86.4% in the placebo group (Δ 3.4%, 95% CI -0.1% to 6.8%). Four-year IDFS for the olaparib group versus placebo group was 82.7% versus 75.4% (Δ 7.3%, 95% CI 3.0% to 11.5%) and 4-year DDFS was 86.5% versus 79.1% (Δ 7.4%, 95% CI 3.6% to 11.3%), respectively. Subset analyses for OS, IDFS, and DDFS demonstrated benefit across major subgroups. No new safety signals were identified including no new cases of acute myeloid leukemia or myelodysplastic syndrome. CONCLUSION With 3.5 years of median follow-up, OlympiA demonstrates statistically significant improvement in OS with adjuvant olaparib compared with placebo for gBRCA1/2pv-associated EBC and maintained improvements in the previously reported, statistically significant endpoints of IDFS and DDFS with no new safety signals.
Collapse
|
10
|
Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, Sablin MP, Campone M, Bonnefoi H, Lefeuvre-Plesse C, Jacot W, Coussy F, Ferrero JM, Emile G, Mouret-Reynier MA, Thery JC, Isambert N, Mege A, Barthelemy P, You B, Hajjaji N, Lacroix L, Rouleau E, Tran-Dien A, Boyault S, Attignon V, Gestraud P, Servant N, Le Tourneau C, Cherif LL, Soubeyran I, Montemurro F, Morel A, Lusque A, Jimenez M, Jacquet A, Gonçalves A, Bachelot T, Bieche I. Genomics to select treatment for patients with metastatic breast cancer. Nature 2022; 610:343-348. [PMID: 36071165 DOI: 10.1038/s41586-022-05068-3] [Citation(s) in RCA: 45] [Impact Index Per Article: 22.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2021] [Accepted: 07/03/2022] [Indexed: 01/04/2023]
Abstract
Cancer progression is driven in part by genomic alterations1. The genomic characterization of cancers has shown interpatient heterogeneity regarding driver alterations2, leading to the concept that generation of genomic profiling in patients with cancer could allow the selection of effective therapies3,4. Although DNA sequencing has been implemented in practice, it remains unclear how to use its results. A total of 1,462 patients with HER2-non-overexpressing metastatic breast cancer were enroled to receive genomic profiling in the SAFIR02-BREAST trial. Two hundred and thirty-eight of these patients were randomized in two trials (nos. NCT02299999 and NCT03386162) comparing the efficacy of maintenance treatment5 with a targeted therapy matched to genomic alteration. Targeted therapies matched to genomics improves progression-free survival when genomic alterations are classified as level I/II according to the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)6 (adjusted hazards ratio (HR): 0.41, 90% confidence interval (CI): 0.27-0.61, P < 0.001), but not when alterations are unselected using ESCAT (adjusted HR: 0.77, 95% CI: 0.56-1.06, P = 0.109). No improvement in progression-free survival was observed in the targeted therapies arm (unadjusted HR: 1.15, 95% CI: 0.76-1.75) for patients presenting with ESCAT alteration beyond level I/II. Patients with germline BRCA1/2 mutations (n = 49) derived high benefit from olaparib (gBRCA1: HR = 0.36, 90% CI: 0.14-0.89; gBRCA2: HR = 0.37, 90% CI: 0.17-0.78). This trial provides evidence that the treatment decision led by genomics should be driven by a framework of target actionability in patients with metastatic breast cancer.
Collapse
Affiliation(s)
- Fabrice Andre
- Department of Medical Oncology, Gustave Roussy, Villejuif, France. .,INSERM U981, Gustave Roussy, Villejuif, France. .,PRISM Center for personalized medicine, Gustave Roussy, Villejuif, France. .,Medical School, Université Paris Saclay, Kremlin Bicetre, France.
| | - Thomas Filleron
- Department of Biostatistics, Institut Claudius Regaud, IUCT oncopole, Toulouse, France
| | - Maud Kamal
- Department of Drug Development and Innovation, Institut Curie, Saint Cloud, France
| | | | - Monica Arnedos
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | - Florence Dalenc
- Department of Medical Oncology, Institut Claudius-Regaud IUCT oncopole and University of Paul Sabatier, Toulouse, France
| | - Marie-Paule Sablin
- Department of Drug Development and Innovation, Institut Curie, Saint Cloud, France.,Department of Medical Oncology, Institut Curie, Paris, France
| | - Mario Campone
- Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, University of Angers, Angers, France
| | - Hervé Bonnefoi
- Department of Medical Oncology, Institut Bergonié INSERM U1218 and Université of Bordeaux, Bordeaux, France
| | | | - William Jacot
- Department of Medical Oncology, Institut du Cancer de Montpellier, Institut de Recherche en Cancérologie de Montpellier INSERM U1194 and Montpellier University, Montpellier, France
| | - Florence Coussy
- Department of Medical Oncology, Institut Curie, Saint-Cloud, France
| | - Jean-Marc Ferrero
- Department of Medical Oncology, Centre Antoine Lacassagne, University Côte d'Azur, Nice, France
| | - George Emile
- Department of Medical Oncology, Centre François Baclesse, Caen, France
| | | | - Jean-Christophe Thery
- Department of Medical Oncology, Centre Hennri Becquerel, University of Medicine of Rouen, Rouen, France
| | - Nicolas Isambert
- Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France
| | - Alice Mege
- Institut Sainte Catherine, Avignon, France
| | | | - Benoit You
- Department of Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Nawale Hajjaji
- Department of Medical Oncology, Centre Oscar Lambret INSERM U1192 PRISM Laboratory and University of Lille, Lille, France
| | - Ludovic Lacroix
- Cancer Genetics Laboratory, Department of Pathology and Medical Biology, Gustave Roussy, Villejuif, France
| | - Etienne Rouleau
- Cancer Genetics Laboratory, Department of Pathology and Medical Biology, Gustave Roussy, Villejuif, France
| | - Alicia Tran-Dien
- INSERM U981, Gustave Roussy, Villejuif, France.,PRISM Center for personalized medicine, Gustave Roussy, Villejuif, France.,Bioinformatic Core Facility, UMS AMMICA, Gustave Roussy, Villejuif, France
| | - Sandrine Boyault
- Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France
| | - Valery Attignon
- Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France
| | - Pierre Gestraud
- Bioinformatics and Computational Systems Biology of Cancer, PSL Research University, Mines Paris Tech, INSERM U900, Paris, France
| | - Nicolas Servant
- Bioinformatics and Computational Systems Biology of Cancer, PSL Research University, Mines Paris Tech, INSERM U900, Paris, France
| | | | - Linda Larbi Cherif
- Department of Drug Development and Innovation, Institut Curie, Saint Cloud, France
| | - Isabelle Soubeyran
- Unit of Molecular Pathology - Department of Biopathology, Institut Bergonié, Bordeaux, France
| | | | - Alain Morel
- Department of Innate Immunity and Immunotherapy, Institut de Cancérologie de l'Ouest - Centre Paul Papin, Angers, France
| | - Amelie Lusque
- Department of Biostatistics, Institut Claudius Regaud, IUCT oncopole, Toulouse, France
| | | | | | - Anthony Gonçalves
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
| | - Thomas Bachelot
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France
| | - Ivan Bieche
- Department of Genetics, Institut Curie, INSERM U1016, Université Paris Cité, Paris, France
| |
Collapse
|
11
|
Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer. Nat Commun 2022; 13:5258. [PMID: 36071033 PMCID: PMC9452562 DOI: 10.1038/s41467-022-32828-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Accepted: 08/17/2022] [Indexed: 12/27/2022] Open
Abstract
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. Here, we show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n = 37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n = 89). We also identified heterozygous RB1 loss as biomarker of acquired resistance and poor clinical outcome. Combination of the CDK4/6 inhibitor ribociclib with the PI3K inhibitor alpelisib showed antitumor activity in estrogen receptor-positive non-basal-like breast cancer patient-derived xenografts, independently of PIK3CA, ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy. Our results offer insights into predicting primary/acquired resistance to CDK4/6 inhibitors and post-progression therapeutic strategies.
Collapse
Affiliation(s)
- Marta Palafox
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Laia Monserrat
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Meritxell Bellet
- Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain
| | - Guillermo Villacampa
- Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Abel Gonzalez-Perez
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain
- Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain
| | - Mafalda Oliveira
- Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain
| | - Fara Brasó-Maristany
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
| | - Nusaibah Ibrahimi
- Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France
- Oncostat U1018, Inserm, University Paris-Saclay, Villejuif, France
| | | | - Leonardo Mina
- Medica Scientia Innovation Research (MedSIR), Barcelona, Spain
| | | | - Andreu Òdena
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Mònica Sánchez-Guixé
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Marta Capelán
- Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain
| | - Analía Azaro
- Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain
| | - Alejandra Bruna
- Preclinical Modelling of Pediatric Cancer Evolution Group, The Institute of Cancer Research, London, UK
| | - Olga Rodríguez
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Marta Guzmán
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Judit Grueso
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Cristina Viaplana
- Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Javier Hernández
- Translational Molecular Pathology, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain
| | - Faye Su
- Novartis Pharmaceuticals, East Hanover, NJ, USA
| | - Kui Lin
- Genentech, Inc., South San Francisco, California, USA
| | - Robert B Clarke
- Breast Biology Group, Manchester Breast Centre, Manchester, UK
| | | | - Joaquín Arribas
- CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - Stefan Michiels
- Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France
- Oncostat U1018, Inserm, University Paris-Saclay, Villejuif, France
| | | | | | - Aleix Prat
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
- University of Barcelona, Barcelona, Spain
- Department of Medical Oncology, Hospital Clinic, Barcelona, Spain
- SOLTI Breast Cancer Research Group, Barcelona, Spain
- Department of Oncology, IOB Institute of Oncology, Barcelona, Spain
| | - Paolo Nuciforo
- Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Rodrigo Dienstmann
- Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Chandra S Verma
- Bioinformatics Institute (A*STAR), Singapore, Singapore
- School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
- Department of Biological Sciences, National University of Singapore, Singapore, Singapore
| | - Nuria Lopez-Bigas
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain
- Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - Maurizio Scaltriti
- Departments of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - Monica Arnedos
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
- Inserm Unit U981, Villejuif, France
| | - Cristina Saura
- Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain
| | - Violeta Serra
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
- CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
| |
Collapse
|
12
|
Blaye C, Darbo É, Debled M, Brouste V, Vélasco V, Pinard C, Larmonier N, Pellegrin I, Tarricone A, Arnedos M, Commeny J, Bonnefoi H, Larmonier C, MacGrogan G. An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy. ESMO Open 2022; 7:100502. [PMID: 35759853 PMCID: PMC9434232 DOI: 10.1016/j.esmoop.2022.100502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Accepted: 04/22/2022] [Indexed: 11/27/2022] Open
Abstract
Background When triple-negative breast cancer (TNBC) patients have residual disease after neoadjuvant chemotherapy (NACT), they have a high risk of metastatic relapse. With immune infiltrate in TNBC being prognostic and predictive of response to treatment, our aim was to develop an immunologic transcriptomic signature using post-NACT samples to predict relapse. Materials and methods We identified 115 samples of residual tumors from post-NACT TNBC patients. We profiled the expression of 770 genes related to cancer microenvironment using the NanoString PanCancer IO360 panel to develop a prognostic transcriptomic signature, and we describe the immune microenvironments of the residual tumors. Results Thirty-eight (33%) patients experienced metastatic relapse. Hierarchical clustering separated patients into five clusters with distinct prognosis based on pathways linked to immune activation, epithelial-to-mesenchymal transition and cell cycle. The immune microenvironment of the residual disease was significantly different between patients who experienced relapse compared to those who did not, the latter having significantly more effector antitumoral immune cells, with significant differences in lymphoid subpopulations. We selected eight genes linked to immunity (BLK, GZMM, CXCR6, LILRA1, SPIB, CCL4, CXCR4, SLAMF7) to develop a transcriptomic signature which could predict relapse in our cohort. This signature was validated in two external cohorts (KMplot and METABRIC). Conclusions Lack of immune activation after NACT is associated with a high risk of distant relapse. We propose a prognostic signature based on immune infiltrate that could lead to targeted therapeutic strategies to improve patient prognosis. Infiltrate of cytotoxic cells is higher in the residual disease of TNBC patients who will not experience metastatic relapse. Underexpression of immune-related pathways is associated with metastatic relapse in residual disease of TNBC patients. An immune gene-based signature can predict metastatic relapse in TNBC patients after NACT.
Collapse
Affiliation(s)
- C Blaye
- Department of Medical Oncology, Institut Bergonié, Bordeaux, France; Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| | - É Darbo
- Univ. Bordeaux, INSERM U1218, ACTION Laboratory, Bordeaux, France
| | - M Debled
- Department of Medical Oncology, Institut Bergonié, Bordeaux, France
| | - V Brouste
- Departments of Clinical Research and Medical Information, Bordeaux, France
| | - V Vélasco
- Biopathology, Institut Bergonié, Bordeaux, France
| | - C Pinard
- Pathology Laboratory, University Hospital of Martinique, Fort de France
| | - N Larmonier
- Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France; Univ. Bordeaux, Bordeaux, France
| | - I Pellegrin
- Service d'Immunologie et Immunogénétique, University Hospital of Bordeaux, Bordeaux, France; Centre de Ressources Biologiques Plurithématique, University Hospital of Bordeaux, Bordeaux, France
| | - A Tarricone
- Service d'Immunologie et Immunogénétique, University Hospital of Bordeaux, Bordeaux, France
| | - M Arnedos
- Department of Medical Oncology, Institut Bergonié, Bordeaux, France
| | - J Commeny
- Department of Surgery, Institut Bergonié, Bordeaux, France
| | - H Bonnefoi
- Department of Medical Oncology, Institut Bergonié, Bordeaux, France; Univ. Bordeaux, INSERM U1218, ACTION Laboratory, Bordeaux, France; Univ. Bordeaux, Bordeaux, France
| | - C Larmonier
- Biopathology, Institut Bergonié, Bordeaux, France
| | - G MacGrogan
- Univ. Bordeaux, INSERM U1218, ACTION Laboratory, Bordeaux, France; Biopathology, Institut Bergonié, Bordeaux, France.
| |
Collapse
|
13
|
LeNoue-Newton ML, Chen SC, Stricker T, Hyman DM, Blauvelt N, Bedard PL, Meric-Bernstam F, Punglia RS, Schrag D, Lepisto EM, Andre F, Smyth L, Dogan S, Yu C, Wathoo C, Levy M, Eli LD, Xu F, Mann G, Lalani AS, Ye F, Micheel CM, Arnedos M. Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE. Clin Cancer Res 2022; 28:2118-2130. [PMID: 35190802 DOI: 10.1158/1078-0432.ccr-21-0885] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 06/21/2021] [Accepted: 02/16/2022] [Indexed: 11/16/2022]
Abstract
PURPOSE We wanted to determine the prognosis and the phenotypic characteristics of hormone receptor-positive advanced breast cancer tumors harboring an ERBB2 mutation in the absence of a HER2 amplification. EXPERIMENTAL DESIGN We retrospectively collected information from the American Association of Cancer Research-Genomics Evidence Neoplasia Information Exchange registry database from patients with hormone receptor-positive, HER2-negative, ERBB2-mutated advanced breast cancer. Phenotypic and co-mutational features, as well as response to treatment and outcome were compared with matched control cases ERBB2 wild type. RESULTS A total of 45 ERBB2-mutant cases were identified for 90 matched controls. The presence of an ERBB2 mutation was not associated with worse outcome determined by overall survival (OS) from first metastatic relapse. No significant differences were observed in phenotypic characteristics apart from higher lobular infiltrating subtype in the ERBB2-mutated group. ERBB2 mutation did not seem to have an impact in response to treatment or time-to-progression (TTP) to endocrine therapy compared with ERBB2 wild type. In the co-mutational analyses, CDH1 mutation was more frequent in the ERBB2-mutated group (FDR < 1). Although not significant, fewer co-occurring ESR1 mutations and more KRAS mutations were identified in the ERBB2-mutated group. CONCLUSIONS ERBB2-activating mutation was not associated with a worse OS from time of first metastatic relapse, or differences in TTP on treatment as compared with a series of matched controls. Although not significant, differences in coexisting mutations (CDH1, ESR1, and KRAS) were noted between the ERBB2-mutated and the control group.
Collapse
Affiliation(s)
| | - Sheau-Chiann Chen
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Thomas Stricker
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee
| | - David M Hyman
- Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Philippe L Bedard
- Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Funda Meric-Bernstam
- Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas
| | - Rinaa S Punglia
- Department of Radiation Oncology, DFCI, Harvard Medical School, Boston, Massachusetts
| | - Deborah Schrag
- Division of Population Sciences and the Department of Medical Oncology, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts
| | - Eva M Lepisto
- Division of Population Sciences and the Department of Medical Oncology, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts
| | - Fabrice Andre
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France
- INSERM Unit, U981, Gustave Roussy Cancer Campus, Villejuif, France
| | - Lillian Smyth
- Memorial Sloan Kettering Cancer Center, New York, New York
| | - Semih Dogan
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France
- INSERM Unit, U981, Gustave Roussy Cancer Campus, Villejuif, France
| | - Celeste Yu
- Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Chetna Wathoo
- Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas
| | - Mia Levy
- Departments of Biomedical Informatics and Medicine, Division of Hematology/Oncology, and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Lisa D Eli
- PUMA Biotechnology, Los Angeles, California
| | - Feng Xu
- PUMA Biotechnology, Los Angeles, California
| | - Grace Mann
- PUMA Biotechnology, Los Angeles, California
| | | | - Fei Ye
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Christine M Micheel
- Department of Medicine, Division of Hematology/Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Monica Arnedos
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France
- INSERM Unit, U981, Gustave Roussy Cancer Campus, Villejuif, France
| |
Collapse
|
14
|
Blaye C, Darbo E, Debled M, Brouste V, Vélasco V, Pinard C, Pellegrin I, Tarricone A, Arnedos M, Commeny J, Bonnefoi H, Larmonier C, Macgrogan G. 8P An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
15
|
André F, Gonçalves A, Filleron T, Dalenc F, Lusque A, Campone M, Sablin MP, Bonnefoi H, Bieche I, Lacroix L, Tran-Dien A, Jimenez M, Jacquet A, Wang Q, Rouleau E, Gentien D, Soubeyran I, Morel A, Arnedos M, Bachelot T. Abstract GS1-10: Clinical utility of molecular tumor profiling: Results from the randomized trial SAFIR02-BREAST. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-gs1-10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: While studies have shown feasibility and reported preliminary evidence of utility, there is no evidence that multigene sequencing improves outcome in patients with metastatic cancer. The aim of the present study was to assess the clinical utility of multigene sequencing and DNA copy number analyses.. Methods: In SAFIR02-BREAST (NCT: 02299999) and SAFIR-PI3K (NCT: 03386162), open-label multicentric phase II randomized trials, patients were selected if they had a Her2-negative metastatic breast cancer eligible to 1st or 2nd line chemotherapy. Patients underwent a pre-treatment biopsy of metastatic disease when feasible, followed by genomic analysis by next generation sequencing and SNParray. After 6 to 8 cycles of induction chemotherapy, patients without progressive disease and presenting an actionable genomic alteration, were randomized between targeted therapies matched to genomic alterations or maintenance chemotherapy. The primary objective was to evaluate whether targeted therapies guided by genomics improves progression-free survival (PFS) as compared to maintenance chemotherapy, in a pooled analyses of SAFIR02-BREAST and SAFIR-PI3K populations. A hierarchical testing was applied. The efficacy of targeted therapies matched to genomic alterations was first tested in patients presenting an ESCAT I/II alteration (ESMO Scale of Actionability of Molecular Targets). If a p value <0.1 was observed in the first step, analyses were then performed in the Intent-to-treat population. Results: Out of the 1462 patients included, 238 (16%) were subsequently randomized between maintenance chemotherapy (n=81) and targeted therapy (n=157). In 115 patients presenting an ESCAT I/II genomic alteration, the median PFS was 9.1 months (90%CI: 7.1-9.8) and 2.8 (90%CI: 2.1-4.8) in matched targeted therapy and maintenance chemotherapy arms respectively (adjusted HR for stratification factors =0.41;90%CI: 0.27-0.61, p<0.001). In the overall population, there was no significant difference in the duration of PFS between the two arms (adjusted HR: 0.77 (95%CI: 0.56- 1.06, p=0.109). ESCAT classification was highly predictive for the benefit of targeted therapies matched to genomic alterations (interaction test, p= 0.004). Targeted therapies matched to genomic alterations were not effective in patients without ESCAT I/II alteration (HR: 1.15, 95%CI: 0.76-1.75). The SNP array analyses (n=926) identified 21 genes altered more frequently in metastases as compared to primary tumors (TCGA+ METABRIC). Of these, focal TERT amplifications were associated with a poor outcome. Focal CDK4 amplifications were observed after resistance to CDK4 inhibitors. Finally, high HRD was associated with longer PFS in patients with BRCA mutation treated with olaparib (HR: 0.32 [95%CI: 0.12;0.83], p=0.013).. Conclusion: SAFIR02/PI3K trials report that the clinical use of multigene sequencing must be driven by a framework of actionability, and identifies new genomic alterations associated with metastatic evolution and drug resistance or sensitivity.
Citation Format: Fabrice André, Anthony Gonçalves, Thomas Filleron, Florence Dalenc, Amélie Lusque, Mario Campone, Marie-Paule Sablin, Hervé Bonnefoi, Ivan Bieche, Ludovic Lacroix, Alicia Tran-Dien, Marta Jimenez, Alexandra Jacquet, Qing Wang, Etienne Rouleau, David Gentien, Isabelle Soubeyran, Alain Morel, Monica Arnedos, Thomas Bachelot. Clinical utility of molecular tumor profiling: Results from the randomized trial SAFIR02-BREAST [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr GS1-10.
Collapse
Affiliation(s)
- Fabrice André
- Gustave Roussy-Department of Medical Oncology, Villejuif, France
| | | | | | | | | | - Mario Campone
- Institut de Cancérologie de l’Ouest, ST-HERBLAIN, France
| | | | | | - Ivan Bieche
- Institut Curie and Paris-Descartes University-Department of Medical Oncology, Paris, France
| | - Ludovic Lacroix
- Gustave Roussy-Department of Medical Biology and Pathology, BMO Unit - AMMICa UMS3655/US23, Villejuif, France
| | - Alicia Tran-Dien
- Gustave Roussy Cancer Campus-Inserm UMR981 and Department of Medical Oncology, Villejuif, France
| | | | | | - Qing Wang
- Centre Léon Bérard-Département de Recherche Translationnelle et d’Innovation, Lyon, France
| | - Etienne Rouleau
- Gustave Roussy-Department of Medical Biology and Pathology, BMO Unit - AMMICa UMS3655/US23, Villejuif, France
| | - David Gentien
- Institut Curie-Genomics Platform, Translational Research Department. PSL University, Paris, France
| | - Isabelle Soubeyran
- Institut Bergonié-nité de Pathologie Moléculaire - Département de Biopathologie, Bordeaux, France
| | - Alain Morel
- ICO- Centre Paul Papin-Department of Innate Immunity and Immunotherapy, Angers, France
| | - Monica Arnedos
- Gustave Roussy-Department of Medical Oncology, Villejuif, France
| | - Thomas Bachelot
- Centre Léon Bérard-Department of Medical Oncology, Lyon, France
| |
Collapse
|
16
|
Campone M, Bachelot T, Treilleux I, Pistilli B, Salleron J, Seegers V, Arnedos M, Loussouarn D, Wang Q, Vanlemmens L, Jimenez M, Rios M, Diéras V, Leroux A, Paintaud G, Rezai K, André F, Lion M, Merlin JL. A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). Eur J Cancer 2021; 158:169-180. [PMID: 34678678 DOI: 10.1016/j.ejca.2021.09.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 09/06/2021] [Accepted: 09/11/2021] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Resistance to trastuzumab in breast cancer is an ongoing challenge. Clinical and biological effects of co-targeting HER2 and mammalian target of rapamycin (mTOR) in patients with HER2-positive early operable breast cancer via the addition of everolimus to preoperative trastuzumab were evaluated in a phase II randomised study. METHODS Patients were randomised 1:1 to receive trastuzumab (4 mg/kg initial dose then 2 mg/kg weekly for 5 weeks) alone or combined with everolimus (10 mg/day for 6 weeks) and then underwent surgery. Tumours were assessed by clinical examination and echography at the baseline and on treatment. The primary end-point was the clinical response rate at 6 weeks. Pathological response and safety were also evaluated. Baseline and surgery tumour samples were assessed by immunohistochemistry and multiplex immunoanalysis for predictive downstream effectors of the PI3K/AKT/mTOR and MAP kinase (MAPK) pathways. RESULTS Eighty-two patients were enrolled, 41 per arm. The clinical response rates were 34.1% and 43.9% with trastuzumab alone and combined with everolimus, respectively. Pathological response rates were 43.6% and 47.5%, respectively. Addition of everolimus increased toxicity, notably mucositis (82.5% versus 5.0%) and rash (57.5% versus 10.0%), but grade III/IV events were rare. No correlation between response to treatments and baseline candidate biomarkers was identified, except for PIK3CA mutations which were found to predict trastuzumab resistance. Significant changes were seen in several MAPK pathway effectors after combination therapy. CONCLUSIONS The addition of everolimus did not improve the efficacy, but induced MAPK signalling. Combination therapy to overcome pathway cross-talk should be considered to maximise the effectiveness of trastuzumab in this setting. ClinicalTrial.gov Identifier NCT00674414.
Collapse
Affiliation(s)
- Mario Campone
- Department of Medical Oncology/ Cancer Research Center UMR-INSERM U892/CNRS 6299/ Bioinformatics Unit, Institut de Cancérologie de L'Ouest, Nantes, France
| | - Thomas Bachelot
- Department of Medical Oncology, Centre Léon Bérard, INSERM U1052, Lyon, France
| | - Isabelle Treilleux
- Department of Pathology and Biopathology, Centre Léon Bérard, Lyon, France
| | | | - Julia Salleron
- Methodology and Biostatistics Unit, Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France
| | - Valérie Seegers
- Oncology Data Factory and Analytics, Institut de Cancérologie de L'Ouest, Nantes, France
| | - Monica Arnedos
- Department of Medicine, Gustave Roussy, Villejuif, France
| | | | - Qing Wang
- Genomic Platform-Cancer Research Center of Lyon, Centre Léon Bérard, Lyon, France
| | | | | | - Maria Rios
- Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France
| | | | - Agnès Leroux
- Department of Biopathology, Institut de Cancérologie de Lorraine, Université de Lorraine, CNRS UMR 7039, CRAN, Vandoeuvre-Les-Nancy, France
| | - Gilles Paintaud
- François Rabelais University, CNRS, UMR 7292, Genetics, Immunotherapy, Chemistry and Cancer, Tours, France
| | - Keyvan Rezai
- Radio-Pharmacology Department, Institut Curie-Hôpital Rene Huguenin, Saint-Cloud, France
| | - Fabrice André
- Department of Medicine, Gustave Roussy, Villejuif, France
| | - Maëva Lion
- Department of Biopathology, Institut de Cancérologie de Lorraine, Université de Lorraine, CNRS UMR 7039, CRAN, Vandoeuvre-Les-Nancy, France
| | - Jean-Louis Merlin
- Department of Biopathology, Institut de Cancérologie de Lorraine, Université de Lorraine, CNRS UMR 7039, CRAN, Vandoeuvre-Les-Nancy, France.
| |
Collapse
|
17
|
Viansone AA, Ammari S, Dercle L, Arnedos M. Optimizing the Management of Cancer Patients Treated With Systemic Therapies During the COVID-19 Pandemic: The New Role of PCR and CT Scan. Front Oncol 2021; 11:560585. [PMID: 34123768 PMCID: PMC8194693 DOI: 10.3389/fonc.2021.560585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Accepted: 03/12/2021] [Indexed: 01/08/2023] Open
Abstract
In late 2019 and early 2020, the world witnessed the outbreak of the SARS-CoV-2 (also referred as COVID-19) in Wuhan, China. Its rapid expansion worldwide and its contagiousness rate have forced the activation of several measures to contain the pandemic, mostly through confinement and identification of infected patients and potential contacts by testing.
Collapse
Affiliation(s)
- Alessandro A. Viansone
- Breast Unit, Department of Medicine, Gustave Roussy Cancer Campus, Villejuif, France
- Breast Unit–Oncology Unit, Department of Medicine, University Hospital of Parma, Parma, Italy
| | - Samy Ammari
- Radiology Department, Gustave Roussy Cancer Campus, Villejuif, France
| | - Laurent Dercle
- Radiology Department, Columbia University Medical Center New York Presbyterian Hospital, New York, NY, United States
| | - Monica Arnedos
- Breast Unit, Department of Medicine, Gustave Roussy Cancer Campus, Villejuif, France
| |
Collapse
|
18
|
Ciruelos EM, Loibl S, Mayer IA, Campone M, Rugo HS, Arnedos M, Iwata H, Conte PF, André F, Reising A, Ma C, Miller M, Babbar N, Juric D. Abstract PD2-06: Clinical outcomes of alpelisib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer with PIK3CA alterations detected in plasma ctDNA by next-generation sequencing: Biomarker analysis from the SOLAR-1 study. Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-pd2-06] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The PI3K pathway is often hyperactivated in cancer as a result of an altered PI3K isoform and/or loss of phosphatase and tensin homolog function. Approximately 40% of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC) have tumors with mutations in PIK3CA, which encodes the α-isoform of PI3K, p110α. These mutations are known to cause hyperactivation of the PI3K pathway, which contributes to cell proliferation, drug resistance, and poor prognoses. Alpelisib (ALP) is an α-selective PI3K inhibitor that, in combination with fulvestrant (FUL), prolonged median progression-free survival (mPFS) in pts with HR+, HER2−, PIK3CA-mutant ABC following progression on/after prior aromatase inhibitor in the phase 3 SOLAR-1 trial. In SOLAR-1, prospective PIK3CA mutation testing was performed on tumor tissue using PCR-based assays. Through retrospective analysis, efficacy of ALP was demonstrated in subgroups of pts with PIK3CA alteration(s) in tumor tissue and mutation(s) in ctDNA, detected by next-generation sequencing (NGS) and PCR, respectively. In this exploratory biomarker analysis, we assessed clinical outcomes of pts with PIK3CA alteration(s), detected in ctDNA by NGS.Methods: SOLAR-1 is a phase 3, randomized, double-blind, placebo-controlled study of ALP 300 mg vs placebo taken daily with FUL 500 mg every 28 days + Cycle 1 Day 15 in men and postmenopausal women with HR+, HER2- ABC. Retrospectively, the full exonic region of the PIK3CA gene was sequenced using the Foundation Medicine 324-gene ctDNA panel in plasma ctDNA collected at baseline. mPFS was assessed using Kaplan-Meier methodology per investigator assessment.Results: Of 572 pts in SOLAR-1, 381 pts (66.6%) across both PIK3CA-mutant and nonmutant cohorts had valid plasma ctDNA data. Of these pts, 193 (50.7%) had a PIK3CA alteration; 168 (87%) had PCR-detectable mutations and 147 (76%) had a single alteration. A total of 70 (36%) and 102 (53%) pts had alterations in exons 9 and 20, respectively. ALP plus FUL prolonged mPFS in pts with PIK3CA alterations detected in plasma ctDNA by NGS (n=101; Table). Clinical benefit was also observed in pts with PCR-detectable mutations (n=88), single mutations (n=83), and pts with mutations in exon 9 (n=34) and exon 20 (n=54). Pt numbers were low, and wide 95% CIs were observed in groups with alterations not detectable by PCR (n=13) and in pts with multiple alterations. Some limitations of this retrospective plasma analysis include that this is a subgroup (66.6%) of the SOLAR-1 pt population and that the subgroup of pts with non-altered PIK3CA included pts with a PIK3CA mutation in their tumor tissue. Conclusions: ALP plus FUL demonstrated clinical benefit in pts with PIK3CA mutations detected in plasma ctDNA by NGS, in pts with single alterations, and in pts with alterations in exons 9 and 20. Results were consistent across pt groups, except in those with alterations not detectable by PCR. In conclusion, these data demonstrate a consistent clinical benefit of ALP plus FUL in various groups of pts with PIK3CA alterations detected in ctDNA by NGS.
Clinical Outcomes of Patients With PIK3CA Alterations Detected in Plasma ctDNA by NGS in SOLAR-1Alpelisib + fulvestrantPlacebo + fulvestrantHR (95% CI)Events/N (%)mPFS, mo (95% CI)Events/N(%)mPFS, mo (95% CI)PIK3CA altered vs non-alteredAltered58/101(57.4)11.04(7.72-16.16)73/92(79.3)3.65(2.86-6.80)0.47(0.33-0.67)Non-altered40/87(46.0)10.87(5.59-16.76)60/101(59.4)5.45(3.75-9.00)0.60(0.40-0.91)PIK3CA: alteration detectable by PCR vs alteration not detectable by PCRDetectable52/88(59.1)12.48(7.36-18.37)66/80(82.5)3.58(2.37-5.65)0.44(0.30-0.64)Not detectable6/13(46.2)8.48(2.69-NA)7/12(58.3)7.39(1.87-12.98)1.12(0.35-3.56)PIK3CA: number of alterationsSingle45/83(54.2)12.88(7.36-18.50)50/64(78.1)3.58(1.87-6.11)0.43(0.28-0.65)Multiple13/18(72.2)9.00(3.68-18.37)23/28(82.1)4.63(3.48-9.63)0.55(0.25-1.20)PIK3CA alterations in exon 9 or exon 20Exon 918/34(52.9)15.21(7.03-NA)29/36(80.6)3.66(2.86-7.36)0.31(0.16-0.61)Exon 2034/54(63.0)10.91(5.72-18.37)40/48(83.3)3.52(1.87-6.11)0.51(0.31-0.82)CI, confidence interval; ctDNA, circulating tumor DNA; HR, hazard ratio; mPFS, median progression-free survival; mo, months; NA, not available; NGS, next-generation sequencing.
Citation Format: Eva M. Ciruelos, Sibylle Loibl, Ingrid A. Mayer, Mario Campone, Hope S. Rugo, Monica Arnedos, Hiroji Iwata, Pier Franco Conte, Fabrice André, Albert Reising, Chong Ma, Michelle Miller, Naveen Babbar, Dejan Juric. Clinical outcomes of alpelisib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer with PIK3CA alterations detected in plasma ctDNA by next-generation sequencing: Biomarker analysis from the SOLAR-1 study [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PD2-06.
Collapse
Affiliation(s)
| | | | - Ingrid A. Mayer
- 3Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TX
| | - Mario Campone
- 4Institut de Cancérologie de l’Ouest, St. Herblain, France
| | - Hope S. Rugo
- 5University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | | | | | | | | | | | - Chong Ma
- 10Novartis Pharmaceuticals Corporation, Cambridge, MA
| | | | - Naveen Babbar
- 10Novartis Pharmaceuticals Corporation, Cambridge, MA
| | - Dejan Juric
- 11Department of Oncology/Hematology, Gillette Center for Women's Cancer, Massachusetts General Hospital Cancer Center, Boston, MA
| |
Collapse
|
19
|
Charles C, Di Meglio A, Arnedos M, Arvis J, Baciarello G, Blanchard P, Djehal N, Dumas A, Hollbecque A, Martin E, Matias M, Menvielle G, Zingarello A, Dauchy S, Vaz-Luis I. QualFatigue study: which factors influence the use of specific interventions for breast cancer survivors with fatigue? A cross-sectional exploratory study. Support Care Cancer 2021; 29:4827-4834. [PMID: 33547524 DOI: 10.1007/s00520-021-06040-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Accepted: 02/02/2021] [Indexed: 12/24/2022]
Abstract
PURPOSE International guidelines recommend specific interventions to reduce cancer-related fatigue (CRF). Evidence suggests underutilization of these interventions among breast cancer survivors. The QualFatigue study aimed to explore the potential factors influencing the use of specific interventions, for relief, in patients with CRF through qualitative analyses. METHODS Patients with stage I-III breast cancer, and CRF ≥4 on a 10-point numerical scale were recruited within 6-24 months at the end of their primary treatment. Semi-structured interviews were performed. Emergent themes were identified using a stepped content analysis (QDA Miner software). RESULTS Data saturation was achieved with 15 interviews. Four main themes emerged as potential sources of influence in the participants' use of specific interventions: (1) expectations regarding the management of CRF, (2) representations of the benefits provided by the interventions, (3) individual physical and psychological conditions, and (4) social and environmental situations. Six key levers came out transversally to optimize the use of specific interventions to relieve CRF: (1) listening and recognition of the individual difficulties and needs; (2) individual and global health assessments; (3) information and advice on how to manage CRF; (4) discussion groups focused on the management of CRF; (5) group activities; and (6) professional and personalized guidance. CONCLUSION This study calls for multi-level action to address many persistent barriers and exploit levers in the management of CRF.
Collapse
Affiliation(s)
- Cécile Charles
- Gustave Roussy, Université Paris-Saclay, 114 Rue Edouard Vaillant, F-94805, Villejuif Cedex, France.
- Laboratoire de Psychopathologie et Processus de Santé (EA 4057), Université Paris Descartes, Sorbonne Paris Cité, 71 avenue Edouard Vaillant, 92100, Boulogne-Billancourt, France.
| | - Antonio Di Meglio
- Inserm, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Monica Arnedos
- Département d'Oncologie Médicale, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Johanna Arvis
- Ligue nationale contre le cancer, 75013, Paris, France
| | - Giulia Baciarello
- Département d'Oncologie Médicale, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Pierre Blanchard
- Département d'Oncologie Médicale, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Nardjes Djehal
- Département d'Oncologie Médicale, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Agnès Dumas
- INSERM (National Institute for Health and Medical Research), Université de Paris, ECEVE UMR 1123, F-75010, Paris, France
| | - Antoine Hollbecque
- Département d'Oncologie Médicale, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Elise Martin
- Inserm, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Margarida Matias
- Département d'Oncologie Médicale, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Gwenn Menvielle
- Institut Pierre Louis d'Epidémiologie et Santé Publique, Sorbonne Université, Inserm, 75012, Paris, France
| | - Anna Zingarello
- Département d'Oncologie Médicale, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Sarah Dauchy
- Gustave Roussy, Université Paris-Saclay, 114 Rue Edouard Vaillant, F-94805, Villejuif Cedex, France
| | - Ines Vaz-Luis
- Inserm, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
- Département d'Oncologie Médicale, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| |
Collapse
|
20
|
Ferrere G, Tidjani Alou M, Liu P, Goubet AG, Fidelle M, Kepp O, Durand S, Iebba V, Fluckiger A, Daillère R, Thelemaque C, Grajeda-Iglesias C, Alves Costa Silva C, Aprahamian F, Lefevre D, Zhao L, Ryffel B, Colomba E, Arnedos M, Drubay D, Rauber C, Raoult D, Asnicar F, Spector T, Segata N, Derosa L, Kroemer G, Zitvogel L. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight 2021; 6:145207. [PMID: 33320838 PMCID: PMC7934884 DOI: 10.1172/jci.insight.145207] [Citation(s) in RCA: 127] [Impact Index Per Article: 42.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Accepted: 12/09/2020] [Indexed: 02/06/2023] Open
Abstract
Limited experimental evidence bridges nutrition and cancer immunosurveillance. Here, we show that ketogenic diet (KD) — or its principal ketone body, 3-hydroxybutyrate (3HB), most specifically in intermittent scheduling — induced T cell–dependent tumor growth retardation of aggressive tumor models. In conditions in which anti–PD-1 alone or in combination with anti–CTLA-4 failed to reduce tumor growth in mice receiving a standard diet, KD, or oral supplementation of 3HB reestablished therapeutic responses. Supplementation of KD with sucrose (which breaks ketogenesis, abolishing 3HB production) or with a pharmacological antagonist of the 3HB receptor GPR109A abolished the antitumor effects. Mechanistically, 3HB prevented the immune checkpoint blockade–linked upregulation of PD-L1 on myeloid cells, while favoring the expansion of CXCR3+ T cells. KD induced compositional changes of the gut microbiota, with distinct species such as Eisenbergiella massiliensis commonly emerging in mice and humans subjected to carbohydrate-low diet interventions and highly correlating with serum concentrations of 3HB. Altogether, these results demonstrate that KD induces a 3HB-mediated antineoplastic effect that relies on T cell–mediated cancer immunosurveillance.
Collapse
Affiliation(s)
| | | | - Peng Liu
- Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France
| | | | | | - Oliver Kepp
- Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France
| | - Sylvère Durand
- Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France
| | - Valerio Iebba
- Department of Medical Sciences, University of Trieste, Trieste, Italy
| | | | | | | | | | | | - Fanny Aprahamian
- Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France
| | - Déborah Lefevre
- Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France
| | - Liwei Zhao
- Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France
| | | | | | | | - Damien Drubay
- Gustave Roussy, Department of Biostatistics and Epidemiology, University Paris-Saclay, Villejuif, France
| | | | - Didier Raoult
- URMITE, Aix Marseille Université, UM63, CNRS 7278, IRD 198, INSERM 1095, IHU-Méditerranée Infection, Marseille, France
| | - Francesco Asnicar
- Department Cellular, computational and integrative biology (CIBIO), University of Trento, Trento, Italy
| | - Tim Spector
- The Department of Twin Research & Genetic Epidemiology, King's College London, United Kingdom
| | - Nicola Segata
- Department Cellular, computational and integrative biology (CIBIO), University of Trento, Trento, Italy
| | - Lisa Derosa
- Gustave Roussy, INSERM U1015, Villejuif, France
| | - Guido Kroemer
- Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France
| | - Laurence Zitvogel
- Gustave Roussy, INSERM U1015, Villejuif, France.,University Paris Saclay, Saint-Aubin, France.,CIC 1428 BIOTHERIS, Gustave Roussy, Villejuif, France
| |
Collapse
|
21
|
Bertho M, Fraisse J, Patsouris A, Cottu P, Arnedos M, Pérol D, Jaffré A, Goncalves A, Lebitasy MP, D’Hondt V, Dalenc F, Ferrero JM, Levy C, Dabakuyo S, Rouzier R, Penault-Llorca F, Uwer L, Eymard JC, Breton M, Chevrot M, Thureau S, Petit T, Simon G, Frénel JS. Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. Ther Adv Med Oncol 2021; 13:1758835920987657. [PMID: 33613700 PMCID: PMC7841864 DOI: 10.1177/1758835920987657] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Accepted: 12/17/2020] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Bone-only (BO) metastatic breast cancer (MBC) is considered a more favorable entity than other MBC presentations. However, only few retrospective series and data from selected randomized controlled trials have been reported so far. METHODS Using the French national multicenter ESME (Epidemiological Strategy and Medico Economics) Data Platform, the primary objective of our study was to compare the overall survival (OS) of patients with BO versus non-BO MBC at diagnosis, with adjustment on main prognostic factors using a propensity score. Secondary objectives were to compare first-line progression-free survival (PFS1), describe treatment patterns, and estimate factors associated with OS. RESULTS Out of 20,095 eligible women, 5041 (22.4%) patients had BO disease [hormone-receptor positive (HR+)/human epidermal growth-factor-receptor-2 negative (HER2-), n = 4 102/13,229 (31%); HER2+, n = 644/3909 (16.5%); HR-/HER2-, n = 295/2 957 (10%)]. BO MBC patients had a better adjusted OS compared with non-BO MBC [52.1 months (95% confidence interval (CI) 50.3-54.1) versus 34.7 months (95% CI 34.0-35.6) respectively]. The 5-year OS rate of BO MBC patients was 43.4% (95% CI 41.7-45.2). They also had a better PFS1 [13.1 months (95% CI 12.6-13.8) versus 8.5 months (95% CI 8.3-8.7), respectively]. This observation could be repeated in all subtypes. BO disease was an independent prognostic factor of OS [hazard ratio 0.68 (95% CI 0.65-0.72), p < 0.0001]. Results were concordant in all analyses. CONCLUSION BO MBC patients have better outcomes compared with non-BO MBC, consistently, through all MBC subtypes.
Collapse
Affiliation(s)
- Marion Bertho
- Department of Medical Oncology, Institut de Cancérologie de l’Ouest – Paul Papin, Angers, France
| | - Julien Fraisse
- Biometrics Unit, Regional Cancer Institute of Montpellier (ICM), Montpellier, France
| | - Anne Patsouris
- Department of Medical Oncology, Institut de Cancérologie de l’Ouest – Paul Papin, Angers, France
| | - Paul Cottu
- Department of Medical Oncology, Institut Curie, Paris, France
| | - Monica Arnedos
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France
| | - David Pérol
- Biostatistic Unit, Clinical Research and Innovation Department, Centre Léon Bérard, Lyon, France
| | - Anne Jaffré
- Department of Medical Information, Institut Bergonié, Bordeaux, France
| | - Anthony Goncalves
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
| | - Marie-Paule Lebitasy
- Clinical Research and Innovation Department, Centre Oscar Lambret, Lille, France
| | - Véronique D’Hondt
- Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France
| | - Florence Dalenc
- Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France
| | - Jean-Marc Ferrero
- Department of Medical Oncology, Institut Centre Antoine Lacassagne, Nice, France
| | - Christelle Levy
- Department of Medical Oncology, Centre François Baclesse, Caen, France
| | - Sandrine Dabakuyo
- National Quality of Life and Cancer Clinical Research Platform, Centre Georges François Leclerc, Dijon, France
| | - Roman Rouzier
- Department of Surgical Oncology, Institut Curie, Saint-Cloud, France
| | | | - Lionel Uwer
- Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès- Nancy, France
| | | | - Mathias Breton
- Department of Medical Information, Centre Eugène Marquis, Rennes, France
| | | | - Sébastien Thureau
- Department of Radiation Oncology, Centre Henri Becquerel, Rouen, France
| | - Thierry Petit
- Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France
| | | | - Jean-Sébastien Frénel
- Department of Medical Oncology, ICO René Gauducheau, Boulevard Jacques Monod, Saint Herblain, Pays de la Loire 44805, France
| |
Collapse
|
22
|
Harding JJ, Cleary JM, Quinn DI, Braña I, Moreno V, Borad MJ, Loi S, Spanggaard I, Park H, Ford JM, Arnedos M, Stemmer SM, De La Fouchardiere C, Viteri Ramirez S, Fountzilas C, Zhang J, Xu F, Lalani AS, Piha-Paul SA, Abou-Alfa GK. Targeting HER2 ( ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT ‘basket’ trial. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.3_suppl.320] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
320 Background: Genomic profiling studies have reported somatic HER2 mutations in ~2–5% of biliary tract cancers (BTC). Clinical data from the SUMMIT study demonstrate that neratinib, a pan-HER irreversible tyrosine kinase inhibitor, has encouraging clinical activity in multiple types of HER2-mutant solid tumor malignancies. Methods: SUMMIT is a multi-histology, open-label, phase II ‘basket’ study of neratinib in patients with somatic HER2 mutations (ClinicalTrials.gov NCT01953926). Patients with activating somatic HER2 mutations with different histologies, including BTC, received neratinib monotherapy (240 mg oral daily). Loperamide prophylaxis was mandatory during cycle 1. Efficacy endpoints: objective response rate (ORR, RECIST v1.1); clinical benefit rate (CBR); duration of response; progression-free survival (PFS). Adverse events (AEs) were assessed by CTCAE v4.0. Genomic profiling from fresh/archival tumor tissues and/or plasma cfDNA was performed retrospectively by next-generation sequencing (MSK-IMPACT). Results: As of 3-Sep-2020, 25 patients with HER2-mutant BTC were enrolled: gallbladder (40%); intrahepatic (24%); extrahepatic (20%); ampulla of Vater (16%). 68% of patients received ≥2 systemic regimens (96% received prior gemcitabine-based regimens). The S310F/Y variant accounted for nearly half of HER2 mutations (n=11). Other HER2 mutations: V777L (n=5); L755S (n=2); V842I (n=2); R678Q (n=2). Confirmed ORR in 25 evaluable patients was 12% (95% CI 3–31%) and CBR was 20% (95% CI 7–41%), including 3 confirmed PRs and 2 patients with SD for ≥16 weeks. Tumor shrinkage was observed in multiple HER2-activating mutations and enriched in gallbladder and extrahepatic subtypes of BTC. Median PFS was 2.8 (95% CI 1.1–3.7) months; median overall survival (OS) was 5.4 (95% CI 3.7–11.7) months. Nine (36%) patients (3 of whom with ECOG PS 2) came off study within 28 (range 6–47) days of treatment due to clinical deterioration (unrelated to study drug) followed by death. The most common treatment-related AEs (any grade) were diarrhea (56%) and vomiting (48%). Diarrhea was the most common Grade 3 event (24%); 4 patients (16%) required a neratinib dose reduction; no patients discontinued treatment due to diarrhea. Conclusions: Neratinib is safe and tolerable in patients with advanced BTC patients and somatic HER2 mutations. The antitumor activity of neratinib appears comparable to current standards of care, with similar PFS and OS in heavily pretreated patients. Analysis of co-occurring oncogenic mutations and response is ongoing, and consideration is being given to neratinib-based combination regimens to further improve outcomes in this setting. Clinical trial information: NCT01953926.
Collapse
Affiliation(s)
| | | | | | - Irene Braña
- Vall d’Hebron University Hospital, Vall d’Hebrón Institute of Oncology, Barcelona, Spain
| | - Victor Moreno
- START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain
| | | | - Sherene Loi
- Peter MacCallum Cancer Centre, Melbourne, Australia
| | - Iben Spanggaard
- Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark
| | - Haeseong Park
- Alvin J Siteman Cancer Center, Washington University, St. Louis, MO
| | | | | | - Salomon M. Stemmer
- Research Institute of Oncology Davidoff Center, Rabin Medical Center, Tel Aviv, Israel
| | | | | | | | - Jie Zhang
- Puma Biotechnology Inc., Los Angeles, CA
| | - Feng Xu
- Puma Biotechnology Inc., Los Angeles, CA
| | | | | | | |
Collapse
|
23
|
Delrieu L, Jacquet E, Segura-Ferlay C, Blanc E, Febvey-Combes O, Friedenreich C, Romieu G, Jacot W, Rios M, Heudel PE, Roemer-Becuwe C, Jouannaud C, Tredan O, Chaigneau L, Arnedos M, Orfeuvre H, Quenel-Tueux N, Jacquin JP, Ferrero JM, Moullet I, Abadie-Lacourtoisie S, Penault-Llorca F, Cox D, Bachelot T. Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer. Sci Rep 2020; 10:10757. [PMID: 32612272 PMCID: PMC7329808 DOI: 10.1038/s41598-020-67431-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Accepted: 06/09/2020] [Indexed: 01/05/2023] Open
Abstract
Benefits of physical activity are widely demonstrated for early stage cancers but few studies have focused on metastatic disease. The purpose of this study was to determine the impact of physical activity on survival in patients with metastatic breast cancer. We conducted a secondary analysis of the national, multicentric, non-randomized, prospective cohort SNPs to Risk of Metastasis (StoRM) study. The level of physical activity was self-reported at inclusion and divided into three categories of physical activity: light level, moderate level, and vigorous level. Overall, 833 patients (56.2%) completed the physical activity questionnaire at baseline on average physical activity during the previous year: 11.6% had a light level of physical activity, 69.0% achieved moderate levels of physical activity and 19.3% reported vigorous levels of physical activity. After adjustment for confounding, physical activity was not statistically significantly associated with overall survival in the whole population. Subgroup analysis identified that both vigorous and moderate physical activity were associated with statistically significantly improved overall survival compared to light physical activity level only in the HER2 positive subgroup (HR 0.23; 95% CI 0.07-0.70, p = 0.01 and HR 0.38; 95% CI 0.15-0.96, p = 0.04). Physical activity done during the previous year was associated with survival in HER2 positive metastatic breast cancer patients. These results suggest that overall survival in metastatic breast cancer patients could be improved through physical activity which should be considered as a complementary intervention for these individuals. The study showed that moderate/vigorous levels of physical activity were associated with better overall survival, and that these associations remained statistically significant in multivariate analysis in the HER2 positive subgroup. These results have clinical relevance and justify the recommendations for physical activity interventions in metastatic breast cancer.
Collapse
Affiliation(s)
- Lidia Delrieu
- Laboratory of Motor Biology (LIBM), EA7424, Vascular Biology and Red Blood Cell Team, Claude Bernard Lyon 1 University, Villeurbanne, France.,Cancer and Environment Department, Centre Léon Bérard, Lyon, France
| | - Emmanuelle Jacquet
- Oncology and Blood Diseases Department, Joseph Fourier University, University Hospital Center, Grenoble, France.
| | - Céline Segura-Ferlay
- Direction of Clinical Research and Innovation (DRCI), Centre Léon Bérard, Lyon, France
| | - Ellen Blanc
- Direction of Clinical Research and Innovation (DRCI), Centre Léon Bérard, Lyon, France
| | - Olivia Febvey-Combes
- Direction of Clinical Research and Innovation (DRCI), Centre Léon Bérard, Lyon, France
| | - Christine Friedenreich
- Department of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Calgary, AB, Canada.,Departments of Oncology and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
| | - Gilles Romieu
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France
| | - William Jacot
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France
| | - Maria Rios
- Department of Medical Oncology, Cancer Institute of Lorraine - Alexis Vautrin, Vandoeuvre Les Nancy Cedex, France
| | | | | | | | | | - Loïc Chaigneau
- Medical Oncology Service, University Regional Hospital Center, Besançon, France
| | - Monica Arnedos
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France
| | - Hubert Orfeuvre
- Medical Oncology Service, Fleyriat Hospital Center, Bourg en Bresse, France
| | | | - Jean-Philippe Jacquin
- Medical Oncology Department, Lucien Neuwirth Oncology Institute, Saint Priest en Jarez, France
| | - Jean-Marc Ferrero
- Medical Oncology Department, Antoine Lacassagne Center, Nice, France
| | | | | | | | - David Cox
- Cancer Research Center of Lyon, INSERM U1052, Centre Léon Berard, Lyon, France
| | | |
Collapse
|
24
|
Collet L, Eberst L, Fraisse J, Debled M, Levy C, Mouret-Reynier MA, Desmoulins I, Goncalves A, Campone M, Ferrero JM, Brain E, Dieras V, Petit T, Simon G, Leheurteur M, Dalenc F, Vanlemmens L, Darlix A, Arnedos M, Bachelot T. Clinical outcome of patients experiencing central nervous system progression on first-line pertuzumab and trastuzumab for HER2-positive metastatic breast cancer in a real-life cohort. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.2527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2527 Background: Isolated central nervous system (CNS) progression on first-line systemic therapy with Trastuzumab (T) and Pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) is a therapeutic challenge. Our aim was to describe the clinical outcome and current treatment strategies for such patients in a large retrospective cohort. Methods: Patients (pts) were selected among all MBC pts included in the French Epidemiological Strategy and Medical Economics (ESME) database involving 18 specialized cancer centers (NCT03275311). CNS progression-free survival (CNS-PFS), progression-free survival (PFS) and overall survival (OS) from diagnostic of brain metastases (BM) were estimated using the Kaplan-Meier method. Results: Between January 2008 and December 2016, 995 pts were treated with first-line T and P for their HER2-positive MBC. They were 55 years old in median, with tumors expressing hormone-receptors in 62%. A total of 132 pts (13%) experienced isolated CNS progression on T and P, with a median time from metastatic diagnosis to CNS progression of 12 months. It was the first CNS progression for 108 pts (82%) while 24 (18%) already had BM at time of metastatic relapse. After CNS progression, T and P were continued for 58% of pts (n = 73). The remaining 47 pts were switched to another HER2-directed therapy (T-DM1 for 57%, T alone or combined with chemotherapy for 36% and lapatinib for 21%). Among those 132 pts, 37% received whole-brain radiotherapy, 18% stereotactic radiation therapy, and 11% surgery. Systemic treatment was combined with CNS-directed therapy for 50% of pts. Median follow-up is 21 months (95%CI: 14.9-25.5) from the diagnosis of CNS metastases. Median OS (mOS) of the 132 pts is 35 months (95%CI: 29.2-53,6), and median PFS 7 months (95%CI: 6.3- 9.2). A total of 77 pts (58.3%) experienced a new CNS progression with a median CNS-PFS of 9 months (95%CI: 7.6-12,0). Patient who stayed on T and P had a significantly better OS in comparison to pts who were switched to another systemic HER2-directed therapy (mOS not evaluable vs23 months), whereas PFS and CNS-PFS were similar between groups. Conclusions: In this real life setting, isolated CNS progression occurred among 13% of pts with HER2+ MBC on first-line treatment with T and P, after a median time of 12 months. Following current ASCO recommendations, continuation of T and P after CNS-directed therapy, seemed to be adequate. Nevertheless, time to subsequent progression is short and better therapeutic options are needed.
Collapse
Affiliation(s)
| | | | - Julien Fraisse
- Institut du Cancer de Montpellier (ICM), Univ Montpellier, Montpellier, France
| | | | - Christelle Levy
- Centre François Baclesse, Department of Medical Oncology, Caen, France
| | | | | | - Anthony Goncalves
- Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France
| | - Mario Campone
- Institut de Cancérologie de l'Ouest, René Gauducheau, St Herblain, France
| | - Jean-Marc Ferrero
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
| | | | | | - Thierry Petit
- Paul Strauss Cancer Center and University of Strasbourg, Strasbourg, France
| | | | | | - Florence Dalenc
- Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France
| | | | - Amelie Darlix
- Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France
| | | | | |
Collapse
|
25
|
Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hasset MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, Kundra R, Sweeney SM, Gao J, Schultz N, Zarski A, Gardos SM, Lee J, Sheffler-Collins S, Park BH, Sawyers CL, André F, Levy M, Meric-Bernstam F, Bedard PL, Iasonos A, Schrag D, Hyman DM. Characteristics and Outcome of AKT1 E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. Cancer Discov 2020; 10:526-535. [PMID: 31924700 DOI: 10.1158/2159-8290.cd-19-1209] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Revised: 12/18/2019] [Accepted: 01/10/2020] [Indexed: 01/10/2023]
Abstract
AKT inhibitors have promising activity in AKT1 E17K-mutant estrogen receptor (ER)-positive metastatic breast cancer, but the natural history of this rare genomic subtype remains unknown. Utilizing AACR Project GENIE, an international clinicogenomic data-sharing consortium, we conducted a comparative analysis of clinical outcomes of patients with matched AKT1 E17K-mutant (n = 153) and AKT1-wild-type (n = 302) metastatic breast cancer. AKT1-mutant cases had similar adjusted overall survival (OS) compared with AKT1-wild-type controls (median OS, 24.1 vs. 29.9, respectively; P = 0.98). AKT1-mutant cases enjoyed longer durations on mTOR inhibitor therapy, an observation previously unrecognized in pivotal clinical trials due to the rarity of this alteration. Other baseline clinicopathologic features, as well as durations on other classes of therapy, were broadly similar. In summary, we demonstrate the feasibility of using a novel and publicly accessible clincogenomic registry to define outcomes in a rare genomically defined cancer subtype, an approach with broad applicability to precision oncology. SIGNIFICANCE: We delineate the natural history of a rare genomically distinct cancer, AKT1 E17K-mutant ER-positive breast cancer, using a publicly accessible registry of real-world patient data, thereby illustrating the potential to inform drug registration through synthetic control data.See related commentary by Castellanos and Baxi, p. 490.
Collapse
Affiliation(s)
| | - Qin Zhou
- Memorial Sloan Kettering Cancer Center, New York, New York
| | - Bastien Nguyen
- Memorial Sloan Kettering Cancer Center, New York, New York
| | - Celeste Yu
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | - Chetna Wathoo
- The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Hugo Horlings
- Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands
| | - Jan Hudecek
- Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands
| | | | - Ritika Kundra
- Memorial Sloan Kettering Cancer Center, New York, New York
| | - Shawn M Sweeney
- American Association for Cancer Research, Philadelphia, Pennsylvania
| | - JianJiong Gao
- Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Andrew Zarski
- Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Jocelyn Lee
- American Association for Cancer Research, Philadelphia, Pennsylvania
| | | | - Ben H Park
- Vanderbilt Ingram Cancer Center, Nashville, Tennessee
| | | | | | - Mia Levy
- Vanderbilt Ingram Cancer Center, Nashville, Tennessee
| | | | | | - Alexia Iasonos
- Memorial Sloan Kettering Cancer Center, New York, New York
| | | | | |
Collapse
|
26
|
Arnedos M, Bayar MA, Cheaib B, Scott V, Bouakka I, Valent A, Adam J, Leroux-Kozal V, Marty V, Rapinat A, Mazouni C, Sarfati B, Bieche I, Balleyguier C, Gentien D, Delaloge S, Lacroix-Triki M, Michiels S, Andre F. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial. Ann Oncol 2019; 29:1755-1762. [PMID: 29893769 DOI: 10.1093/annonc/mdy202] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Background The cyclin-dependent kinase 4 (CDK4)/6 inhibitor Palbociclib is a new standard treatment in hormone-receptor positive breast cancer patients. No predictive biomarkers have been identified and no pharmacodynamics has properly been described so far. Patients and methods Patients with early-breast cancer were randomized 3 : 1 to oral palbociclib 125 mg daily for 14 days until the day before the surgery versus no treatment. Primary objective was antiproliferative response defined as a natural logarithm of Ki67 expression at day 15 below 1. Secondary end points were subgroups analyses and safety. Exploratory analyses included search for predictive biomarkers. Immunostainings (Ki67, RB, pRB, p16, pAKT, pER, pCDK2, CyclinD1), FISH (CCND1) and gene expression (GE) arrays were carried out at baseline and at surgery. In addition, activating PIK3CA and AKT1 mutations were assessed at baseline. Results 74 patients were allocated to palbociclib and 26 to control. Most patients (93%) were hormone-receptor (HR)-positive, whereas 8% were HER2-positive. Palbociclib led to significantly more antiproliferative responses when compared with control (58% versus 12%, P < 0.001), and to a significantly higher Ki67 decrease (P < 0.001). In the HR-positive/HER2-negative subgroup, this antiproliferative effect was even more marked in the palbociclib arm when compared with control (70% versus 9%, P < 0.001). Palbociclib treatment led also to a significantly higher decrease from baseline in phospho-Rb when compared with control (P < 0.001). Among treated patients, changes in Ki67 correlated with changes in phospho-Rb (Spearman rank r = 0.41, P < 0.0001). GE analyses confirmed a major effect on proliferation and cell cycle genes. Among treated patients, CCNE2 expression was significantly more decreased in antiproliferative responders versus nonresponders (P = 0.006). Conclusion Short-term preoperative palbociclib decreases Ki67 in early-breast cancer patients. Early decrease of Rb phosphorylation correlates with drug's effect on cell proliferation and could potentially identify patients with primary resistance. Clinical trial registration NCT02008734.
Collapse
Affiliation(s)
- M Arnedos
- Department of Cancer Medicine, Breast Cancer Committee, Gustave Roussy, Villejuif, France; INSERM Unit 981, Gustave Roussy, Villejuif, France.
| | - M A Bayar
- Statistics and Epidemiology Unit, Gustave Roussy, Villejuif, France; CESP, Medical School, INSERM, Université Paris Saclay, Villejuif, France
| | - B Cheaib
- Department of Cancer Medicine, Breast Cancer Committee, Gustave Roussy, Villejuif, France
| | - V Scott
- INSERM Unit 981, Gustave Roussy, Villejuif, France
| | - I Bouakka
- INSERM Unit 981, Gustave Roussy, Villejuif, France
| | - A Valent
- Department of Biology and Pathology, Gustave Roussy, Villejuif, France
| | - J Adam
- INSERM Unit 981, Gustave Roussy, Villejuif, France; Department of Biology and Pathology, Gustave Roussy, Villejuif, France
| | - V Leroux-Kozal
- Department of Biology and Pathology, Gustave Roussy, Villejuif, France
| | - V Marty
- Hystopathology and Translational Research Department, Gustave Roussy, Villejuif, France
| | - A Rapinat
- Translational Research Department, Genomics Platform, Institut Curie, PSL Research University, Paris, France
| | - C Mazouni
- Department of Surgery, Gustave Roussy, Villejuif, France
| | - B Sarfati
- Department of Surgery, Gustave Roussy, Villejuif, France
| | - I Bieche
- Department of Genetics, Institut Curie, Paris, France
| | - C Balleyguier
- Department of Radiology, Gustave Roussy, Villejuif, France
| | - D Gentien
- Translational Research Department, Genomics Platform, Institut Curie, PSL Research University, Paris, France
| | - S Delaloge
- Department of Cancer Medicine, Breast Cancer Committee, Gustave Roussy, Villejuif, France
| | - M Lacroix-Triki
- Department of Biology and Pathology, Gustave Roussy, Villejuif, France
| | - S Michiels
- Statistics and Epidemiology Unit, Gustave Roussy, Villejuif, France; CESP, Medical School, INSERM, Université Paris Saclay, Villejuif, France
| | - F Andre
- Department of Cancer Medicine, Breast Cancer Committee, Gustave Roussy, Villejuif, France; INSERM Unit 981, Gustave Roussy, Villejuif, France
| |
Collapse
|
27
|
Smyth LM, Piha-Paul SA, Won HH, Schram AM, Saura C, Loi S, Lu J, Shapiro GI, Juric D, Mayer IA, Arteaga CL, de la Fuente MI, Brufksy AM, Spanggaard I, Mau-Sørensen M, Arnedos M, Moreno V, Boni V, Sohn J, Schwartzberg LS, Gonzàlez-Farré X, Cervantes A, Bidard FC, Gorelick AN, Lanman RB, Nagy RJ, Ulaner GA, Chandarlapaty S, Jhaveri K, Gavrila EI, Zimel C, Selcuklu SD, Melcer M, Samoila A, Cai Y, Scaltriti M, Mann G, Xu F, Eli LD, Dujka M, Lalani AS, Bryce R, Baselga J, Taylor BS, Solit DB, Meric-Bernstam F, Hyman DM. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discov 2019; 10:198-213. [PMID: 31806627 DOI: 10.1158/2159-8290.cd-19-0966] [Citation(s) in RCA: 78] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2019] [Revised: 10/23/2019] [Accepted: 12/02/2019] [Indexed: 11/16/2022]
Abstract
HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER+ patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating HER2 or HER3 alterations were associated with poor treatment outcome. Similarly, acquisition of multiple HER2-activating events, as well as gatekeeper alterations, were observed at disease progression in a high proportion of patients deriving clinical benefit from neratinib. Collectively, these data define HER2 mutations as a therapeutic target in breast cancer and suggest that coexistence of additional HER signaling alterations may promote both de novo and acquired resistance to neratinib. SIGNIFICANCE: HER2 mutations define a targetable breast cancer subset, although sensitivity to irreversible HER kinase inhibition appears to be modified by the presence of concurrent activating genomic events in the pathway. These findings have implications for potential future combinatorial approaches and broader therapeutic development for this genomically defined subset of breast cancer.This article is highlighted in the In This Issue feature, p. 161.
Collapse
Affiliation(s)
- Lillian M Smyth
- Memorial Sloan Kettering Cancer Center, New York, New York.,St. Vincent's University Hospital, Dublin, Ireland
| | | | - Helen H Won
- Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Cristina Saura
- Vall d'Hebron University Hospital, Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain
| | - Sherene Loi
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - Janice Lu
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California
| | | | - Dejan Juric
- Dana-Farber Cancer Institute, Boston, Massachusetts
| | | | - Carlos L Arteaga
- The University of Texas Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas
| | | | - Adam M Brufksy
- University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania
| | | | | | | | | | - Valentina Boni
- START Madrid Hospital Universitario HM Sanchinarro, Madrid, Spain
| | - Joohyuk Sohn
- Yonsei Cancer Center, University College of Medicine, Seoul, Korea
| | | | | | - Andrés Cervantes
- CIBERONC, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain
| | | | | | | | | | - Gary A Ulaner
- Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Komal Jhaveri
- Memorial Sloan Kettering Cancer Center, New York, New York
| | | | | | | | - Myra Melcer
- Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Yanyan Cai
- Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Grace Mann
- Puma Biotechnology, Inc., Los Angeles, California
| | - Feng Xu
- Puma Biotechnology, Inc., Los Angeles, California
| | - Lisa D Eli
- Puma Biotechnology, Inc., Los Angeles, California
| | | | | | | | - José Baselga
- Memorial Sloan Kettering Cancer Center, New York, New York
| | - Barry S Taylor
- Memorial Sloan Kettering Cancer Center, New York, New York
| | - David B Solit
- Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - David M Hyman
- Memorial Sloan Kettering Cancer Center, New York, New York.
| |
Collapse
|
28
|
Abstract
The phosphoinositide 3 (PI3)-kinase/Akt signaling pathway has always been a focus of interest in breast cancer due to its role in cell growth, cell proliferation, cell migration and deregulated apoptosis. Its activation has been linked to endocrine resistance and worse prognosis in certain subgroups of breast cancer. In addition, deregulation of the PI3K/Akt pathway including PIK3CA activating mutation is frequently present in breast cancer. Multiple efforts have been carried out to target this pathway, initially with pan-PI3K inhibitors with some hint of activity but hampered by their limiting side-effects. A recent large randomized trial in patients with endocrine-resistant PIK3CA-mutant hormone receptor (HR)-positive tumors led to the approval of the first PI3K inhibitor, alpelisib, in combination with fulvestrant. The specificity of alpelisib against the p110α catalytic isoform provided additional efficacy and a better toxicity profile. In this review, we summarize the main research with PI3K inhibitors in breast cancer and we provide some insight of potential future combinations of this treatment in breast cancer patients.
Collapse
Affiliation(s)
- B Verret
- Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France
| | - J Cortes
- IOB Institute of Oncology, Quiron, Madrid & Barcelona
- Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona
- Medica Scientia Innovation Research (MedSIR), Valencia, Spain
- Medica Scientia Innovation Research (MedSIR), New York, USA
| | - T Bachelot
- Medical Oncology Department, Centre Léon Bérard, Lyon
| | - F Andre
- Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France
- Inserm Unit U981, Gustave Roussy Cancer Campus, Villejuif
- Université Paris Sud, Paris-Saclay, France
| | - M Arnedos
- Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France
- Inserm Unit U981, Gustave Roussy Cancer Campus, Villejuif
| |
Collapse
|
29
|
Arnedos M, Gligorov J. St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patients' overtreatment and breaking the bank? Ann Oncol 2019; 30:1533-1535. [PMID: 31504122 DOI: 10.1093/annonc/mdz292] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/09/2023] Open
Affiliation(s)
- M Arnedos
- Breast Unit, Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
| | - J Gligorov
- Medical Oncology Department, Tenon Hospital, Inserm U938, Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Tenon Hospital, Paris, France
| |
Collapse
|
30
|
Messaoudene M, Mourikis TP, Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A, Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, Jacquelot N, Ghiringhelli F, Caignard A, Eggermont AMM, Kroemer G, Marabelle A, Arnedos M, Vicier C, Dogan S, Jaulin F, Sammut SJ, Cope W, Caldas C, Delaloge S, McGranahan N, André F, Zitvogel L. T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants. Ann Oncol 2019; 30:934-944. [PMID: 30924846 PMCID: PMC7614969 DOI: 10.1093/annonc/mdz112] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Tumor-infiltrating lymphocytes (TILs) represent a prognostic factor for survival in primary breast cancer (BC). Nonetheless, neoepitope load and TILs cytolytic activity are modest in BC, compromising the efficacy of immune-activating antibodies, which do not yet compete against immunogenic chemotherapy. PATIENTS AND METHODS We analyzed by functional flow cytometry the immune dynamics of primary and metastatic axillary nodes [metastatic lymph nodes (mLN)] in early BC (EBC) after exposure to T-cell bispecific antibodies (TCB) bridging CD3ε and human epidermal growth factor receptor 2 (HER2) or Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5), before and after chemotherapy. Human leukocyte antigen (HLA) class I loss was assessed by whole exome sequencing and immunohistochemistry. One hundred primary BC, 64 surrounding 'healthy tissue' and 24 mLN-related parameters were analyzed. RESULTS HLA loss of heterozygosity was observed in EBC, at a clonal and subclonal level and was associated with regulatory T cells and T-cell immunoglobulin and mucin-domain-3 expression restraining the immuno-stimulatory effects of neoadjuvant chemotherapy. TCB bridging CD3ε and HER2 or CEACAM5 could bypass major histocompatibility complex (MHC) class I loss, partially rescuing T-cell functions in mLN. CONCLUSION TCB should be developed in BC to circumvent low MHC/peptide complexes.
Collapse
Affiliation(s)
- M Messaoudene
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France
| | - T P Mourikis
- Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK
| | - J Michels
- Gustave Roussy Cancer Campus (GRCC), Villejuif; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif
| | - Y Fu
- Gustave Roussy Cancer Campus (GRCC), Villejuif
| | - M Bonvalet
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France
| | - M Lacroix-Trikki
- Gustave Roussy Cancer Campus (GRCC), Villejuif; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
| | - B Routy
- Gustave Roussy Cancer Campus (GRCC), Villejuif; Universitéde Montréal Hospital Research Centre (CRCHUM), Onco-Hematology Department, Montreal University Hospital Center (CHUM), Montréal, Québec, Canada
| | - A Fluckiger
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
| | - S Rusakiewicz
- Center of Experimental Therapeutics (CET), Department of Oncology, Lausanne University Hospital, CHUV, Lausanne, Switzerland
| | - M P Roberti
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
| | - S Cotteret
- Gustave Roussy Cancer Campus (GRCC), Villejuif
| | - C Flament
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
| | - V Poirier-Colame
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
| | - N Jacquelot
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif
| | - F Ghiringhelli
- Georges-François Leclerc center, Medical Oncology, Dijon
| | - A Caignard
- INSERM U1160, University Institute for Haematology, Saint Louis hospital, Paris
| | | | - G Kroemer
- Gustave Roussy Cancer Campus (GRCC), Villejuif; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus, Cordeliers Research Center, INSERM, U1138, Université Paris Descartes, Sorbonne Paris Cité; Université Pierre et Marie Curie; Pôle de Biologie, Européen Georges Pompidou Hospital, AP-HP, Paris
| | - A Marabelle
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Gustave Roussy Cancer Campus (GRCC), Drug Development Department (DITEP), Villejuif
| | - M Arnedos
- Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif
| | - C Vicier
- Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France
| | - S Dogan
- Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif; Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France
| | - F Jaulin
- Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif; Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France
| | - S-J Sammut
- Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge
| | - W Cope
- Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge; Cancer Research UK Cancer Centre and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - C Caldas
- Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge
| | - S Delaloge
- Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif
| | - N McGranahan
- Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK
| | - F André
- Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif; Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France
| | - L Zitvogel
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
| |
Collapse
|
31
|
Bachelot TD, Treilleux I, Schiffler C, Bieche I, Campone M, Patsouris A, Arnedos M, Cottu PH, Jacquin JP, Dalenc F, Attignon V, Rouleau E, Morel A, Legrand F, Jimenez M, Andre F. mTORC1 activation assessed in metastatic sample to predict outcome in patients with metastatic breast cancer treated with everolimus-exemestan: Results from the SAFIRTOR study. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.1024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1024 Background: Using samples from TAMRAD study (Treilleux, Ann Oncol, 2015), we previously reported that p4EBP1, a downstream protein of mTOR, was associated with higher benefit to everolimus (eve). SAFIRTOR study was designed to validate clinical utility of this biomarker. Methods: Patients (pts) with ER+, HER2 negative, AI resistant MBC were prospectively included (NCT02444390). All pts had a biopsy of a metastatic site and were then treated with standard eve + exemestane (exe) combination. The primary end point was to validate that p4EBP1 expression is associated with longer PFS in patients treated with eve. 120 evaluable pts were needed for the pre planed statistical analysis. All samples were collected and processed in a standardized procedure in order to allow phophoproteins IHC staining. In addition to p4EBP1, we explored prognostic value of pS6K, pAkt, PTEN and LKB1, together with genomic alterations assessed by NGS and CGH arrays. Results: 150 pts were included, 30 pts had no adequate sample, and further 13 had missing clinical data, 107 were evaluable for primary objective. Median age was 62, they had previously progressed on AI treatment, either in the adjuvant (22 pts) or the metastatic setting (83 pts). 20 were considered as primary hormone resistant, 87 as secondary resistant. The median Allread score for p4EBP1 was 5.5 (range: 0-6.5). Analysis of the primary endpoint showed that p4EBP1 staining above the median is associated with a longer PFS on eve+exe. (median PFS: 9.3 months, 95CI 6.3-13.1 for high p4EBP1 versus 5.8 months, 95CI 3.7-7.8 for low p4EBP1, p = 0.02). Prognostic value of high pEBP1 remained significant when assessed in a multivariate analysis along classical clinico-biological prognostic factors for MBC (HR 0.57, 95%CI 0.38-0.88, p = 0.01). In this AI resistant population, the tumor of 42 (46%), 33 (35%) and 5 (5.3%) pts carried an activating mutation for ESR1, PIK3CA and AKT1, respectively. None of these mutational statuses were correlated to outcome. Conclusions: This prospective study validates p4EBP1 expression analysis to select patients most likely to benefit from everolimus + exemestane. Clinical trial information: NCT02444390.
Collapse
Affiliation(s)
| | | | | | | | - Mario Campone
- Institut de Cancérologie de l'Ouest, René Gauducheau, St Herblain, France
| | - Anne Patsouris
- Institute of West Cancerology Paul Papin, Angers, France
| | | | | | - Jean-Philippe Jacquin
- GINECO-Institut de Cancérologie de la Loire Lucien Neuwirth, Saint-Priest-En-Jarez, France
| | - Florence Dalenc
- Department of Medicalo Oncology, Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France
| | | | | | - Alain Morel
- CRLCC Paul Papin, CRNA INSERM 892, Angers, France
| | | | | | | |
Collapse
|
32
|
Patsouris A, Tredan O, Nenciu D, Tran-Dien A, Campion L, Goncalves A, Arnedos M, Sablin MP, Gouraud W, Jimenez M, Droin N, Bieche I, Callens C, Loehr A, Vicier C, Andre F. RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD). J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.1092] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1092 Background: PARP-inhibitors improve PFS in mBC patients (pts) harboring a gBRCA mutation (mut). However, unlike ovarian cancer, there is no evidence until now that this class of agents has efficacy in gBRCA wild-type (WT) pts. In RUBY, we evaluated rucaparib in gBRCA WT mBC pts, and whose tumor present with HRD as assessed by genome-wide Loss of Heterozygosity (LOH) score. Methods: 713 gBRCA WT women with HER2- mBC, initiating a first metastatic chemo, were screened for high (≥18%) genomic tumor LOH generated from a SNP array on metastatic sample. Eligible pts with a high LOH score or somatic (s) BRCA mut and ≥1 prior chemo regimen were proposed to enter RUBY and receive oral rucaparib 600 mg BID continuously in 28-day cycles until disease progression. The primary endpoint was clinical benefit rate (CBR), defined by complete (CR) and partial response (PR) or stable disease (SD) ≥16 weeks. We used a Simon’s two-stage design (p0=20%; p1=40%), responses in ≥4/17 pts were expected to move to second step, and ≥11/37 pts to be considered of clinical interest (α=10% and power of 90%). Whole genome sequencing (WGS) was performed retrospectively to further assess potential biomarkers of PARP inhibitor response. Results: Tumors from 221 (31%) pts were LOH high. 41 pts were enrolled, including 4 pts with sBRCA mut. Median prior metastatic chemo lines was 2 (1-5), 17 pts had TNBC at diagnosis. As of 14 Jan 2019, 16 pts were alive, 5 are still on treatment. The median number of cycles was 2 (1 -20), and 37/40 patients were evaluable for CBR. 5 pts (13.5%) demonstrated clinical benefit (1 CR [LOH high], 3 PR [2 LOH high, 1 sBRCA2] and 1 SD>31 weeks [sBRCA1]). 19 pts had grade 3-4 toxicities. 3 pts discontinued due to toxicity. 4/5 responders pts had their tumor profiled by WGS: preliminary analyses showed that 4 pts presented high large scale state transitions, and 3 presented a somatic biallelic loss of function in HR-related genes. The fifth responder harbored a mut on gPALB2 and sBRCA2 at inclusion. Conclusions: In this study, rucaparib demonstrates antitumor activity in a subset of gBRCA WT mBC pts whose tumor has high LOH. Final analyses of WGS will provide insights about HRD signatures and drivers alterations associated with response. Clinical trial information: NCT02505048.
Collapse
Affiliation(s)
- Anne Patsouris
- Institute of West Cancerology Paul Papin, Angers, France
| | - Olivier Tredan
- Département d'Oncologie Médicale, Centre Léon Bérard, Lyon, France
| | | | | | - Loic Campion
- Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain, France
| | - Anthony Goncalves
- Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France
| | | | | | - Wilfried Gouraud
- Unité Mixte de Génomique du Cancer-Institut de Cancérologie de l'Ouest, Saint Herblain Cedex, France
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Smyth L, Saura C, Piha-Paul S, Lu J, Mayer I, Brufksy A, Spanggaard I, Arnedos M, Cutler R, Hyman D. Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz095.029] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, André F, Bayar MA, Michiels S, Zhang Z, Giorgetti C, Arnedos M, Huang Bartlett C, Cristofanilli M. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. J Clin Oncol 2019; 37:1169-1178. [PMID: 30807234 PMCID: PMC6506420 DOI: 10.1200/jco.18.00925] [Citation(s) in RCA: 237] [Impact Index Per Article: 47.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
PURPOSE A large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib to fulvestrant. METHODS The PALOMA-3 (ClinicalTrials.gov identifier: NCT01942135) trial randomly assigned 521 endocrine-pretreated patients with metastatic breast cancer to receive palbociclib plus fulvestrant or placebo plus fulvestrant. Primary analysis was first conducted on 10 genes on the basis of pathway biology and evidence from previous studies followed by a systematic panel-wide search among 2,534 cancer-related genes. The association of gene expression with the effect of palbociclib on progression-free survival (PFS) was evaluated using Cox proportional hazards regression analysis, with gene expression as a continuous variable or dichotomized by median. An independent breast cancer cohort from the Preoperative Palbociclib (POP) Clinical Trial (ClinicalTrials.gov identifier: NCT02008734) was used for validation, in 61 patients with primary breast cancer treated with 2 weeks of palbociclib. RESULTS In the PALOMA-3 trial, 302 patients had tumor tissue analyzed (palbociclib arm, 194 patients; placebo arm, 108 patients). Palbociclib efficacy was lower in patients with high versus low cyclin E1 (CCNE1) mRNA expression (median PFS: palbociclib arm, 7.6 v 14.1 months; placebo arm, 4.0 v 4.8 months, respectively; interaction P unadjusted = .00238; false discovery rate–adjusted P = .0238). CCNE1 mRNA was more predictive in metastatic than in archival primary biopsy tissue samples. No significant interaction was found between treatment and expression levels of CDK4, CDK6, cyclin D1, and RB1. Palbociclib was efficacious in both luminal A and luminal B tumors. High CCNE1 mRNA expression was associated with poor antiproliferative activity of palbociclib in the POP trial (P = .005). CONCLUSION Addition of palbociclib to fulvestrant demonstrated efficacy in all biomarker groups, although high CCNE1 mRNA expression was associated with relative resistance to palbociclib.
Collapse
Affiliation(s)
- Nicholas C Turner
- 1 Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
| | | | | | - Sherene Loi
- 3 Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
| | | | | | | | - Nadia Harbeck
- 7 Ludwig Maximilian University of Munich, Munich, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Smyth LM, Piha-Paul SA, Saura C, Loi S, Lu J, Shapiro GI, Juric D, Mayer IA, Arteaga C, de la Fuente M, Brufksy AM, Mau-Sørensen M, Arnedos M, Moreno V, Sohn JH, Schwartzberg L, Gonzàlez-Farré X, Cervantes A, Mann G, Shahin S, Cutler RE, Eli LD, Xu F, Bagulho T, Lalani AS, Bryce R, Solit DB, Hyman DM, Meric-Bernstam F, Baselga J. Abstract PD3-06: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd3-06] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2 mutations define a rare subset of metastatic breast cancer (MBC) with a unique mechanism of oncogenic addiction to HER2 signaling. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, has demonstrated single-agent clinical activity in HER2-mutant MBC. In HER2-mutant, HR+ MBC, neratinib + fulvestrant (N+F) appears synergistic vs single-agent neratinib, possibly due to more complete inhibition of bi-directional signaling between HER2 and estrogen receptors. Here we describe interim efficacy results of the expanded HER2-mutant, HR+ MBC cohort treated with N+F from SUMMIT (NCT01953926).
Methods: HR+ MBC patients (pts) with HER2 mutations documented by local testing received oral neratinib 240mg qd and intramuscular fulvestrant (labeled dose). Intensive loperamide prophylaxis was mandatory during cycle 1. Efficacy endpoints include objective response rate at week 8 (ORR8); confirmed objective response rate (ORR); clinical benefit rate (CBR); duration of response (DOR); progression-free survival (PFS); response was assessed by RECIST 1.1 and/or PET Response Criteria. Genomic profiling from fresh/archival tumor tissues and/or plasma cfDNA was performed retrospectively by next-generation sequencing (MSK-IMPACT).
Results: As of 18 May 2018, 46 HER2-mutant HR+ MBC pts have been treated with N+F. Most pts were pretreated, with 91% having received prior anti-cancer medication for MBC (range 0–10). ORR was 33% and median DOR in the 15 pts with a confirmed response was 9.2 months (95% CI 3.9–18.5). Twenty-four pts had prior fulvestrant exposure, and 19 had received prior CDK4/6i-based therapy. Clinical activity was observed with ORRs of 17% and 26% in prior fulvestrant-treated and prior CDK4/6i-treated pts, respectively. ORRs by HER2 mutation were: V777L 63% (5/8 pts); S310F/Y 67% (4/6 pts); G778_P780dup 50% (3/6 pts). Diarrhea was the most common adverse event (grade 3, 24%; grade 4, 0%). Median cumulative duration of grade 3 diarrhea was 3 days. There were no treatment discontinuations due to diarrhea.
Neratinib + fulvestrantOutcomeaAll patients (N=46)Prior fulvestrant (N=24)Prior CDK4/6i-based therapy (N=19)ORR8 – n (%)19 (41.3)8 (33.3)7 (36.8)95% CI27.0–56.815.6–55.316.3–61.6ORR – n (%)15 (32.6)4 (16.7)5 (26.3)95% CI19.5–48.04.7–37.49.1–51.2DOR for each responder, months 5.6b; 9.2; 9.6b; 18.55.6b; 5.7b; 9.3; 9.6b; 12.9bCBR – n (%)27 (58.7)11 (45.8)9 (47.4)95% CI43.2–73.025.6–67.224.4–71.1Median (95% CI) time to event,c monthsPFS3.9 (3.6–5.7)3.7 (3.5–12.8)3.9 (1.9–NA)DOR9.2 (3.9–18.5)NANAaFor pts with both RECIST- and PET-evaluable lesions, the best of either RECIST or PET response was used to determine response; the earliest progression by RECIST or PET was used for progression; bPt has not progressed; cKaplan-Meier analysis; NA, not applicable
Conclusions: N+F demonstrates encouraging clinical activity with durable responses in heavily pretreated pts with HER2-mutant, HR+ MBC. Of note, responses were observed in pts who had received prior fulvestrant or CDK4/6 inhibitors. No new safety signals were identified; the rate of diarrhea was similar to single-agent neratinib and not dose limiting. Updated data after additional follow-up and genomic data will be presented.
Citation Format: Smyth LM, Piha-Paul SA, Saura C, Loi S, Lu J, Shapiro GI, Juric D, Mayer IA, Arteaga C, de la Fuente M, Brufksy AM, Mau-Sørensen M, Arnedos M, Moreno V, Sohn J-H, Schwartzberg L, Gonzàlez-Farré X, Cervantes A, Mann G, Shahin S, Cutler, Jr. RE, Eli LD, Xu F, Bagulho T, Lalani AS, Bryce R, Solit DB, Hyman DM, Meric-Bernstam F, Baselga J. Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD3-06.
Collapse
Affiliation(s)
- LM Smyth
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - SA Piha-Paul
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - C Saura
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - S Loi
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - J Lu
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - GI Shapiro
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - D Juric
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - IA Mayer
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - C Arteaga
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - M de la Fuente
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - AM Brufksy
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - M Mau-Sørensen
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - M Arnedos
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - V Moreno
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - J-H Sohn
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - L Schwartzberg
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - X Gonzàlez-Farré
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - A Cervantes
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - G Mann
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - S Shahin
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - RE Cutler
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - LD Eli
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - F Xu
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - T Bagulho
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - AS Lalani
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - R Bryce
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - DB Solit
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - DM Hyman
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - F Meric-Bernstam
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| | - J Baselga
- Memorial Sloan Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Houston, TX; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Massachusetts Hospital Cancer Center, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; Miller School of Medicine, University of Miami, Miami, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; Rigshospitalet, Copenhagen, Denmark; Institut Gustave Roussy, Paris, France; START Madrid Fundación Jímenez Díaz, Madrid, Spain; Yonsei Cancer Center, University College of Medicine, Seoul, Korea; West Cancer Center, University of Tennessee, Memphis, TN; Hospital Universitari Quirón Dexeus, Barcelona, Spain; Hospital Clínico Universitario, University of Valencia, Valencia, Spain; Puma Biotechnology Inc., Los Angeles, CA
| |
Collapse
|
36
|
Moindjie H, Rodrigues-Ferreira S, Dujaric M, Servant N, Asselain B, Arnedos M, Pierga J, André F, Nahmias C. PO-497 Microtubule regulatory proteins as predictive biomarkers of taxane-based chemoresistance in breast cancer? ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
37
|
Patsouris A, Tredan O, Campion L, Goncalves A, Arnedos M, Sablin MP, Jézéquel P, Jimenez M, Pezzella V, Bieche I, Callens C, Loehr A, Nenciu D, Vicier C, Andre F. An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.tps1112] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Anne Patsouris
- Institute of West Cancerology Paul Papin, Angers, France
| | - Olivier Tredan
- Département d'Oncologie Médicale, Centre Léon Bérard, Lyon, France
| | - Loic Campion
- Institut de Cancérologie de l'Ouest - René Gauducheau, Saint-Herblain, France
| | - Anthony Goncalves
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
| | | | | | | | | | | | | | | | | | | | | | - Fabrice Andre
- Institut Gustave-Roussy, Université Paris Sud, Villejuif, France
| |
Collapse
|
38
|
Boulle G, Bayle A, Deutsch E, Arnedos M, Rivera S. EP-1291: Clinical guidelines for breast cancer drugs and radiotherapy based on combination safety data. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31601-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
39
|
Arnedos M, Rusquec P, Morelle M, Lebreton C, Jacquet E, Emile G, Aires J, Debled M, Frenel JS, Augereau P, Cheaib B, Levy C, Bachelot T. Abstract P5-21-11: Benefit from palbociclib and fulvestrant based on previous fulvestrant and/or everolimus treatment. Based on a cohort of over 200 patients treated in a French compassionate program. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: CDK4/6 inhibitors have been approved in the recent years for the treatment of advanced hormone receptor-positive breast cancer. For patients with resistance to previous endocrine therapy, the approval is based on the results of the PALOMA-3 trial testing palbociclib in addition to fulvestrant observing a progression-free survival (PFS) of 9.2 months. Nevertheless, in this study no previous treatment with fulvestrant was allowed and no information had been reported of efficacy after everolimus administration.
Patients and methods: We collected information from patients treated with palbociclib + fulvestrant in the context of a French compassionate access. We aimed at determining the benefit of this treatment in a real population to provide information about PFS in non-selected patients as well as efficacy of palbociclib and fulvestrant in patients previously treated with fulvestrant and/or everolimus. Median PFS were assessed by Kaplan-Meier survival analysis and compared with log-rank test.
Results: 206 patients were identified from 5 institutions. Mean age at treatment was 61 years (range 28 – 85). 55% presented with visceral disease. Lines at where palbociclib + fulvestrant treatment was administered were as follows: 1% 1st line, 8.3% 2nd line, 19.4% 3rd line, 13.6% 4th line, 10.2% 5th lignes and the remaining 47.6% had received ≥6 lines (median: 5 lines, range 1 to 15).
A total of 48% patients had previously been treated with fulvestrant. In a subsample of patient where the information was available (n=146), 67.8% patients had received everolimus in combination with endocrine therapy before palbociclib administration.
A total of 77 patients were still on treatment. Median PFS on fulvestrant-palbociclib treatment at the date of data cut-off was of 5.46 months (95% CI; 4.6 to 6.6 months). In a univariate analysis, there were no significant differences in median PFS for patients treated or not with previous fulvestrant, suggesting a potential effect of palbociclib to recover sensitivity to fulvestrant (4.7 months for previous fulvestrant treatment [95% CI 4.07 - 6.3 months] vs 6.1 months for no previous fulvestrant [95% CI; 6.3 - 8.02 months], p=0.3559).
Similarly, in the subsample of n=146 patients where information about previous everolimus treatment was available at data cut-off, benefit from palbociclib-fulvestrant was not affected by previous everolimus treatment (median PFS 4.8 months for previously treated [95% CI; 4.01 -7.8 months] vs 5.4 months for the untreated everolimus group [95% CI; 4.07 - 9.59 months], p=0.374).
Conclusions: Fulvestrant-palbociclib in the real life is associated with a median PFS of 5.5 months, which is below the results provided in the PALOMA-3 trial, reflecting a much more advanced population. Importantly, neither previous everolimus treatment nor fulvestrant therapy affected benefit from fulvestrant-palbociclib in this population in univariate analyses suggesting a potential recovery of fulvestrant sensitivity with CDK4/6 inhibition. Results from multivariate analyses and more detailed information about patients' characteristics and benefit from previous therapies will be provided.
Citation Format: Arnedos M, Rusquec P, Morelle M, Lebreton C, Jacquet E, Emile G, Aires J, Debled M, Frenel J-S, Augereau P, Cheaib B, Levy C, Bachelot T. Benefit from palbociclib and fulvestrant based on previous fulvestrant and/or everolimus treatment. Based on a cohort of over 200 patients treated in a French compassionate program [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-11.
Collapse
Affiliation(s)
- M Arnedos
- Gustave Roussy Cancer Campus, Villejuif, France; Institut Cancerologie Ouest, Nantes, France; Centre Leon Bedard, Lyon, France; Institut Bergonie, Bordeaux, France; Centre François Baclesse, Caen, France; Hospital San Pedro de Alcántara, Caceres, Spain; Institut Cancerologie Ouest, Angers, France
| | - P Rusquec
- Gustave Roussy Cancer Campus, Villejuif, France; Institut Cancerologie Ouest, Nantes, France; Centre Leon Bedard, Lyon, France; Institut Bergonie, Bordeaux, France; Centre François Baclesse, Caen, France; Hospital San Pedro de Alcántara, Caceres, Spain; Institut Cancerologie Ouest, Angers, France
| | - M Morelle
- Gustave Roussy Cancer Campus, Villejuif, France; Institut Cancerologie Ouest, Nantes, France; Centre Leon Bedard, Lyon, France; Institut Bergonie, Bordeaux, France; Centre François Baclesse, Caen, France; Hospital San Pedro de Alcántara, Caceres, Spain; Institut Cancerologie Ouest, Angers, France
| | - C Lebreton
- Gustave Roussy Cancer Campus, Villejuif, France; Institut Cancerologie Ouest, Nantes, France; Centre Leon Bedard, Lyon, France; Institut Bergonie, Bordeaux, France; Centre François Baclesse, Caen, France; Hospital San Pedro de Alcántara, Caceres, Spain; Institut Cancerologie Ouest, Angers, France
| | - E Jacquet
- Gustave Roussy Cancer Campus, Villejuif, France; Institut Cancerologie Ouest, Nantes, France; Centre Leon Bedard, Lyon, France; Institut Bergonie, Bordeaux, France; Centre François Baclesse, Caen, France; Hospital San Pedro de Alcántara, Caceres, Spain; Institut Cancerologie Ouest, Angers, France
| | - G Emile
- Gustave Roussy Cancer Campus, Villejuif, France; Institut Cancerologie Ouest, Nantes, France; Centre Leon Bedard, Lyon, France; Institut Bergonie, Bordeaux, France; Centre François Baclesse, Caen, France; Hospital San Pedro de Alcántara, Caceres, Spain; Institut Cancerologie Ouest, Angers, France
| | - J Aires
- Gustave Roussy Cancer Campus, Villejuif, France; Institut Cancerologie Ouest, Nantes, France; Centre Leon Bedard, Lyon, France; Institut Bergonie, Bordeaux, France; Centre François Baclesse, Caen, France; Hospital San Pedro de Alcántara, Caceres, Spain; Institut Cancerologie Ouest, Angers, France
| | - M Debled
- Gustave Roussy Cancer Campus, Villejuif, France; Institut Cancerologie Ouest, Nantes, France; Centre Leon Bedard, Lyon, France; Institut Bergonie, Bordeaux, France; Centre François Baclesse, Caen, France; Hospital San Pedro de Alcántara, Caceres, Spain; Institut Cancerologie Ouest, Angers, France
| | - J-S Frenel
- Gustave Roussy Cancer Campus, Villejuif, France; Institut Cancerologie Ouest, Nantes, France; Centre Leon Bedard, Lyon, France; Institut Bergonie, Bordeaux, France; Centre François Baclesse, Caen, France; Hospital San Pedro de Alcántara, Caceres, Spain; Institut Cancerologie Ouest, Angers, France
| | - P Augereau
- Gustave Roussy Cancer Campus, Villejuif, France; Institut Cancerologie Ouest, Nantes, France; Centre Leon Bedard, Lyon, France; Institut Bergonie, Bordeaux, France; Centre François Baclesse, Caen, France; Hospital San Pedro de Alcántara, Caceres, Spain; Institut Cancerologie Ouest, Angers, France
| | - B Cheaib
- Gustave Roussy Cancer Campus, Villejuif, France; Institut Cancerologie Ouest, Nantes, France; Centre Leon Bedard, Lyon, France; Institut Bergonie, Bordeaux, France; Centre François Baclesse, Caen, France; Hospital San Pedro de Alcántara, Caceres, Spain; Institut Cancerologie Ouest, Angers, France
| | - C Levy
- Gustave Roussy Cancer Campus, Villejuif, France; Institut Cancerologie Ouest, Nantes, France; Centre Leon Bedard, Lyon, France; Institut Bergonie, Bordeaux, France; Centre François Baclesse, Caen, France; Hospital San Pedro de Alcántara, Caceres, Spain; Institut Cancerologie Ouest, Angers, France
| | - T Bachelot
- Gustave Roussy Cancer Campus, Villejuif, France; Institut Cancerologie Ouest, Nantes, France; Centre Leon Bedard, Lyon, France; Institut Bergonie, Bordeaux, France; Centre François Baclesse, Caen, France; Hospital San Pedro de Alcántara, Caceres, Spain; Institut Cancerologie Ouest, Angers, France
| |
Collapse
|
40
|
Lefeuvre-Plesse C, Lusque A, Bieche I, Lacroix L, Arnedos M, Campone M, Dalenc F, Gonçalves A, Le Du F, Jacquet A, Bonnefoi H, Attignon V, Sablin MP, Soubeyran I, Jézéquel P, Ferrero JM, Isambert N, Levy C, Filleron T, Bachelot T, André F. Characteristics of the Metastatic Breast Cancer Population with PIK3CA Mutation in the Randomized Phase II Study SAFIR02 Breast (UCBG-0105/1304). Breast 2017. [DOI: 10.1016/s0960-9776(17)30686-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
41
|
Cox D, Blanc E, Romieu G, Rios M, Becuwe C, Jouannaud C, Chaigneau L, Arnedos M, Orfeuvre H, Petit T, Quenel Tueux N, Jacquin JP, Ferrero JM, Abadie Lacourtoisie S, Penault-Llorca F, Segura-Ferlay C, Moullet I, Bachelot T, Pivot X. SToRM: A clinical cohort to identify genetic variability related to metastatic phenotypes. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Formisano L, Lu Y, Jansen VM, Bauer JA, Hanker AB, Sanders ME, González-Ericsson P, Kim S, Arnedos M, André F, Arteaga CL. Abstract 1008: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-1008] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The CDK4/6 inhibitor palbociclib was recently approved in combination with endocrine therapy for treatment of ER+ metastatic breast cancer. The goal of this study was to discover mechanisms of resistance to ER antagonists alone and in combination with CDK4/6 inhibitors. To achieve this goal, we used lentiviral vectors to individually express 559 human kinase open reading frames (ORFs) in ER+ MCF7 human breast cancer cells treated with fulvestrant ± the CDK4/6 inhibitor ribociclib (Novartis). In MCF7 cells treated with fulvestrant alone or with ribociclib, we identified 21 and 17 kinases, respectively, which induced a >30% increase in cell viability compared to control cells; 11 of these kinases overlapped in both treatment groups. In a secondary screen, MCF7 cells were stably transduced with V5-tagged lentiviruses expressing the positive ‘hits’ for treatment with fulvestrant/ribociclib. Five of 11 kinases (FGFR1, FRK, HCK, FGR, CRKL) were confirmed to induce resistance to fulvestrant/palbociclib and fulvestrant/ribociblib. Survey of TCGA for copy number alterations and/or expression of these five genes showed only FGFR1 to be amplified/overexpressed in 17% of ER+ breast cancers. Experiments in vitro showed that ER+/FGFR1-amplified (amp) MDA-134, CAMA-1 and HCC1500 human breast cancer cells and MCF7 cells stably transduced with FGFR1 were relatively resistant to estrogen deprivation, fulvestrant and fulvestrant/palbociclib compared to non-FGFR1 amp MCF7 cells. This resistance was abrogated by treatment with the FGFR tyrosine kinase inhibitor (TKI) lucitanib. Treatment with fulvestrant or palbociclib, each alone, modestly delayed growth of ER+/FGFR1-amp breast cancer patient-derived xenografts (PDX) established in nude mice. However, addition of the FGFR TKI erdafitinib to fulvestrant/palbociclib resulted in marked PDX regressions in all mice without associated toxicity. Treatment of FGFR-amp cells with FGF-2 strongly induced CCND1 (cyclin D1) expression. Downregulation of CCND1 with CCND1 RNAi oligonucleotides or kinase inhibition with erdafitinib restored sensitivity of FGFR1-amp cells to fulvestrant/palbociclib. Conversely, overexpression of CCND1 in MCF7 cells induced resistance to estrogen deprivation and fulvestrant ± palbociclib. At this time, we are examining whether FGFR1 amplification measured by FISH correlates with maintenance of proliferation (Ki67) in 110 patients with ER+/HER2- breast cancer treated with palbociclib for 14 days immediately before surgery (Arnedos et al. ASCO 2016). In summary, using a gain-of-function ORF kinome screen, we identified FGFR1 amplification as a mechanism of resistance to anti-ER therapies ± CDK4/6 inhibitors. Based on these data we propose FGFR inhibitors should be tested in combination with ER antagonists and CDK4/6 inhibitors in patients with ER+/FGFR amplified breast cancer.
Citation Format: Luigi Formisano, Yao Lu, Valerie M. Jansen, Joshua A. Bauer, Ariella B. Hanker, Melinda E. Sanders, Paula González-Ericsson, Sunkyu Kim, Monica Arnedos, Fabrice André, Carlos L. Arteaga. Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1008. doi:10.1158/1538-7445.AM2017-1008
Collapse
Affiliation(s)
| | - Yao Lu
- 1Vanderbilt University, Nashville, TN
| | | | | | | | | | | | - Sunkyu Kim
- 2Novartis Pharmaceuticals Corporation, NJ
| | | | | | | |
Collapse
|
43
|
Schram A, Won HH, Andre F, Arnedos M, Meric - Bernstam F, Bedard PL, Shaw KR, Horlings H, Micheel C, Park BH, Mann G, Lalani AS, Smyth L, Solit DB, Schrag D, Levy MA, Rollins BJ, Routbort M, Sawyers CL, Lepisto E, Berger MF, Hyman DM. Abstract LB-103: Landscape of somatic ERBB2 Mutations: Findings from AACR GENIE and comparison to ongoing ERBB2 mutant basket study. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-lb-103] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: AACR GENIE is an international data-sharing project that aggregates clinical-grade cancer genomic data. As a demonstration of utility, we evaluated the landscape of ERBB2 mutations in the first 18,486 patients included in this registry and compared it to the first 100 patients enrolled in an ongoing international Phase 2 SUMMIT ‘basket’ study of the pan-HER inhibitor neratinib in ERBB2 mutant solid tumors (NCT01953926). Results: ERBB2 mutations were identified in 2.8% (519/18,486) of patients in the GENIE cohort and observed at all participating centers. In total, there were 482 missense, 66 indels, 19 truncating mutations, and 14 structural variants. A total of 263 unique missense mutations were observed including 12 at previously identified hotspots which accounted for 69.2% of all missense mutations. 35 unique cancer types were represented. The tumor types with the highest proportion of ERBB2 mutations were bladder (12.8%, 82/641), breast (3.9%, 87/2230), colorectal (3.3%, 70/2102), and NSCLC (3%, 90/3006). Among patients with copy number data available (91%) 11% had concurrent ERBB2 amplification, most often in breast cancer. The most frequently observed alterations in ERBB2, adjusted for differing exon coverage between panels, was S310F/Y in 0.46% of the GENIE cohort (12.6% of samples with ERBB2 alterations), Y772_A775dup in 0.21% (6.9%), R678Q in 0.17% (4.5%), L755S in 0.16% (5.2%), V777L in 0.12% (3.8%), and V842I in 0.09% (3.1%). The distribution of specific ERBB2 variants differed significantly by tumor type with exon 20 insertions being most common in NSCLC (44.4%, 40/90), L755S (18.9%, 11/92) in breast, S310F/Y (26.9%, 28/104) in bladder, and V842I (13.9%, 10/72) in colorectal cancer. Structural variants included intragenic deletions (n=4) and fusions involving various partners including GRB7 (n=2), and one each of C1orf87, PPIL6, HEXIM2, THRA, ASIC2, BCA3, WIPF2. The frequencies of ERBB2 mutant cancer types observed in the GENIE cohort were generally comparable to those enrolled to the neratinib basket study including NSCLC (17 vs 22%, respectively), breast (16.4 vs 24%), bladder (15.5 vs 14%), colorectal (13.2 vs 17%), and endometrial (4.2 vs 6%). At the variant level, S310F/Y was less prevalent in GENIE compared to the neratinib study (12.6 vs 24%) while all other mutations were generally similar including L755S (5.2 vs 9%), R678Q (4.5 vs 2%), Y772_A775dup (6.9 vs 13%), V777L (3.8 vs 9%), and V842I (3.1 vs 6%). Conclusion: GENIE confirms that a diversity of ERBB2 mutations are prevalent across a variety of tumor types in patients with advanced cancer. The genomic landscape of ERBB2 mutations was largely similar in the population based GENIE cohort and the neratinib SUMMIT study, providing the first direct evidence that basket study enrollment accurately reflects the true landscape of the target alteration.
Citation Format: Alison Schram, Helen H. Won, Fabrice Andre, Monica Arnedos, Funda Meric - Bernstam, Philippe L. Bedard, Kenna R. Shaw, Hugo Horlings, Christine Micheel, Ben Ho Park, Grace Mann, Alshad S. Lalani, Lillian Smyth, David B. Solit, Deborah Schrag, Mia A. Levy, Barrett J. Rollins, Mark Routbort, Charles L. Sawyers, Eva Lepisto, Michael F. Berger, David M. Hyman, on behalf of the AACR Project GENIE Consortium. Landscape of somatic ERBB2 Mutations: Findings from AACR GENIE and comparison to ongoing ERBB2 mutant basket study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr LB-103. doi:10.1158/1538-7445.AM2017-LB-103
Collapse
Affiliation(s)
- Alison Schram
- 1Memorial Sloan Kettering Cancer Center, New York, NY
| | - Helen H. Won
- 1Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | | | | | | | - Hugo Horlings
- 6Netherland Cancer Institute, Amsterdam, Netherlands
| | | | - Ben Ho Park
- 8Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, MD
| | | | | | - Lillian Smyth
- 1Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | - Mia A. Levy
- 7Vanderbilt - Ingram Cancer Center, Nashville, TN
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Jobard E, Trédan O, Bachelot T, Vigneron AM, Aït-Oukhatar CM, Arnedos M, Rios M, Bonneterre J, Diéras V, Jimenez M, Merlin JL, Campone M, Elena-Herrmann B. Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients. Oncotarget 2017; 8:83570-83584. [PMID: 29137365 PMCID: PMC5663537 DOI: 10.18632/oncotarget.18784] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2017] [Accepted: 05/23/2017] [Indexed: 12/11/2022] Open
Abstract
The mammalian target of rapamycin complex 1 (mTORC1) is an attractive target for HER-2 positive breast cancer therapy because of its key role in protein translation regulation, cell growth and metabolism. We present here a metabolomic investigation exploring the impact of mTOR inhibition on serum metabolic profiles from patients with non-metastatic breast cancer overexpressing HER-2. Baseline, treatment-related and post-treatment serum samples were analyzed for 79 patients participating in the French clinical trial RADHER, in which randomized patients with HER-2 positive breast cancer received either trastuzumab alone (arm T) or a trastuzumab and everolimus combination (arm T+E). Longitudinal series of NMR serum metabolic profiles were exploited to investigate treatment effects on the patients metabolism over time, in both group. Trastuzumab and everolimus combination induces faster changes in patients metabolism than trastuzumab alone, visible after only one week of treatment as well as a residual effect detectable up to three weeks after ending the treatment. These metabolic fingerprints highlight the involvement of several metabolic pathways reflecting a systemic effect, particularly on the liver and visceral fat. Comparison of serum metabolic profiles between the two arms shows that everolimus, an mTORC1 inhibitor, is responsible for host metabolism modifications observed in arm T+E. In HER-2 positive breast cancer, our metabolomic approach confirms a fast and persistent host metabolism modification caused by mTOR inhibition.
Collapse
Affiliation(s)
- Elodie Jobard
- Université de Lyon, Institut des Sciences Analytiques, UMR 5280, CNRS, Université Lyon 1, ENS de Lyon, Villeurbanne, France.,Université de Lyon, Centre Léon Bérard, Département d'oncologie médicale, Lyon, France
| | - Olivier Trédan
- Université de Lyon, Centre Léon Bérard, Département d'oncologie médicale, Lyon, France
| | - Thomas Bachelot
- Université de Lyon, Centre Léon Bérard, Département d'oncologie médicale, Lyon, France
| | - Arnaud M Vigneron
- Université de Lyon, Centre de Cancérologie de Lyon, UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
| | | | - Monica Arnedos
- Department of Medicine, Gustave Roussy, Villejuif, France
| | - Maria Rios
- Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France
| | | | | | | | - Jean-Louis Merlin
- CNRS UMR7039 CRAN, Université de Lorraine, Vandoeuvre-les-Nancy, France.,Department of Biopathology Unit, Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France
| | - Mario Campone
- Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, France
| | - Bénédicte Elena-Herrmann
- Université de Lyon, Institut des Sciences Analytiques, UMR 5280, CNRS, Université Lyon 1, ENS de Lyon, Villeurbanne, France
| |
Collapse
|
45
|
Gonçalves A, Bachelot T, Lusque A, Arnedos M, Campone M, Bièche I, Lacroix L, Pierron G, Dalenc F, Filleron T, Sablin MP, Jimenez M, Ferrero JM, Lefeuvre-Plesse C, Bonnefoi H, Attignon V, Soubeyran I, Jezequel P, Commo F, André F. Abstract PD1-08: High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR02 BREAST (UCBG-0105/1304). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd1-08] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background A genomic-driven therapeutic strategy in metastatic breast cancer (MBC) was recently demonstrated as feasible in the clinical practice, but its actual impact on patient outcome remains elusive. SAFIR02 study is an ongoing national multicentric phase II randomized trial evaluating targeted therapies matching specific genomic alterations (GA) administered as maintenance after objective response and/or stable disease obtained with chemotherapy in HER2-negative MBC patients. This analysis reports on feasibility of the procedure and the rate of identified actionable targets.
Methods Eligible MBC patients (PS=0/1, first- or second-line of chemotherapy, HER2-negative/hormone receptor (HR)-negative or endocrine resistant HR-positive; measurable per RECIST 1.1; accessible to tumor biopsy; no bone metastases-only disease, no major organ dysfunction) were subjected to tumor biopsy for genomic analysis (CGH arrays, Affymetrix Cytoscan; NGS, Ion Torrent PGM, AmpliSeq, panel of around 50 genes). Actionable GA were identified and corresponding targeted therapies were proposed by a multidisciplinary tumor board (MTB). Patients received cytotoxic-based treatment at physician's choice and those with stable or responding disease after 6 to 8 cycles (or at least 4 if stopped for toxicity reason) and targetable GA, were offered randomization between targeted therapy or chemotherapy maintenance until progression or intolerance (main study). Since January 2016, an amendment was made to propose to patients without targetable alteration a randomization between anti-PD-L1 (MEDI4736) or standard chemotherapy maintenance (substudy).
Results Between March 2014 and May 2016, 457 patients have been enrolled at 21 centers. Genomic analyses could not be obtained in 107 cases (23%) due to either biopsy failure (n= 40; 9%) or low cellularity (n=67; 14%). Of the 307 patients reviewed by the MTB, 197 (64%) had an actionable GA, including PIK3CA-PIK3CB-PIK3R1 (n=51), FGF4 or FGFR1/2 (n= 42), BRCA1/2 (n=15), AKT1/2/3 (n=13), BRAF/KRAS/NRAS (n=13), HER2/3 (n=10), NF1-FRS2 (n=10), MTOR-RPTOR-TSC2 (n=8), PTEN (n=7), STK11 (n=7), IGF1R (n=7), EGFR (n=5). Therapeutic proposals by MTB included AZD5363 (n=71), AZD4547 (n=42), AZD2014 (n=23), selumetinib (n=23), olaparib (n=16), AZD8931 (n=15), vandetanib (n=5), bicalutamide (n=2). In an exploratory analysis involving 157 patients, the rate of targeted therapy proposal by MTB markedly differed between triple-negative patients (TNBC; 24 of 48, 50%) and HER2-negative/HR-positive patients (92 of 109, 84%; p=6.14. 10-6, Chi-2 test). At the time of the analysis, 85 patients have been randomized (main study, 68; substudy, 17). Causes of randomization failure (n=108) included disease progression (n=45) or death (n=25), non-eligibility criteria (n=27), patient/physician's decision (n=11).
Conclusion A large number of patients had identified targetable GA. Of note, the rate of targeted therapeutic proposal was significantly lower in TNBC than in HER2-negative/HR-positive patients. Rapidly progressing disease may impede ultimate randomization.
Citation Format: Gonçalves A, Bachelot T, Lusque A, Arnedos M, Campone M, Bièche I, Lacroix L, Pierron G, Dalenc F, Filleron T, Sablin M-P, Jimenez M, Ferrero J-M, Lefeuvre-Plesse C, Bonnefoi H, Attignon V, Soubeyran I, Jezequel P, Commo F, André F. High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR02 BREAST (UCBG-0105/1304) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD1-08.
Collapse
Affiliation(s)
- A Gonçalves
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - T Bachelot
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - A Lusque
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - M Arnedos
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - M Campone
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - I Bièche
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - L Lacroix
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - G Pierron
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - F Dalenc
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - T Filleron
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - M-P Sablin
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - M Jimenez
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - J-M Ferrero
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - C Lefeuvre-Plesse
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - H Bonnefoi
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - V Attignon
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - I Soubeyran
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - P Jezequel
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - F Commo
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - F André
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| |
Collapse
|
46
|
Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria JC, Massard C, Lévy C, Arnedos M, Lacroix-Triki M, Garrabey J, Boursin Y, Deloger M, Fu Y, Commo F, Scott V, Lacroix L, Dieci MV, Kamal M, Diéras V, Gonçalves A, Ferrerro JM, Romieu G, Vanlemmens L, Mouret Reynier MA, Théry JC, Le Du F, Guiu S, Dalenc F, Clapisson G, Bonnefoi H, Jimenez M, Le Tourneau C, André F. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. PLoS Med 2016; 13:e1002201. [PMID: 28027327 PMCID: PMC5189935 DOI: 10.1371/journal.pmed.1002201] [Citation(s) in RCA: 270] [Impact Index Per Article: 33.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2016] [Accepted: 11/11/2016] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Major advances have been achieved in the characterization of early breast cancer (eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes, yet limited information is available on the genomic profile of this disease. This study aims to decipher mutational profiles of mBC using next-generation sequencing. METHODS AND FINDINGS Whole-exome sequencing was performed on 216 tumor-blood pairs from mBC patients who underwent a biopsy in the context of the SAFIR01, SAFIR02, SHIVA, or Molecular Screening for Cancer Treatment Optimization (MOSCATO) prospective trials. Mutational profiles from 772 primary breast tumors from The Cancer Genome Atlas (TCGA) were used as a reference for comparing primary and mBC mutational profiles. Twelve genes (TP53, PIK3CA, GATA3, ESR1, MAP3K1, CDH1, AKT1, MAP2K4, RB1, PTEN, CBFB, and CDKN2A) were identified as significantly mutated in mBC (false discovery rate [FDR] < 0.1). Eight genes (ESR1, FSIP2, FRAS1, OSBPL3, EDC4, PALB2, IGFN1, and AGRN) were more frequently mutated in mBC as compared to eBC (FDR < 0.01). ESR1 was identified both as a driver and as a metastatic gene (n = 22, odds ratio = 29, 95% CI [9-155], p = 1.2e-12) and also presented with focal amplification (n = 9) for a total of 31 mBCs with either ESR1 mutation or amplification, including 27 hormone receptor positive (HR+) and HER2 negative (HER2-) mBCs (19%). HR+/HER2- mBC presented a high prevalence of mutations on genes located on the mechanistic target of rapamycin (mTOR) pathway (TSC1 and TSC2) as compared to HR+/HER2- eBC (respectively 6% and 0.7%, p = 0.0004). Other actionable genes were more frequently mutated in HR+ mBC, including ERBB4 (n = 8), NOTCH3 (n = 7), and ALK (n = 7). Analysis of mutational signatures revealed a significant increase in APOBEC-mediated mutagenesis in HR+/HER2- metastatic tumors as compared to primary TCGA samples (p < 2e-16). The main limitations of this study include the absence of bone metastases and the size of the cohort, which might not have allowed the identification of rare mutations and their effect on survival. CONCLUSIONS This work reports the results of the analysis of the first large-scale study on mutation profiles of mBC. This study revealed genomic alterations and mutational signatures involved in the resistance to therapies, including actionable mutations.
Collapse
Affiliation(s)
| | - Thomas Bachelot
- Department of Medical Oncology, Centre Léon Bérard, Inserm U1052, Lyon, France
| | - Thomas Filleron
- Biostatistics Department, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France
| | | | - Mario Campone
- Department of Medical Oncology, Institut de Cancérologie de l’Ouest, Nantes, France
| | - Jean-Charles Soria
- INSERM Unit U981, Gustave Roussy, Villejuif, France
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
- Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre, France
- Drug Development Department (DITEP), Gustave Roussy, Villejuif, France
| | | | - Christelle Lévy
- Department of Medical Oncology, Centre François Baclesse, Caen, France
| | - Monica Arnedos
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | | | | | - Yannick Boursin
- Bioinformatics core facility, Gustave Roussy, Villejuif, France
| | - Marc Deloger
- Bioinformatics core facility, Gustave Roussy, Villejuif, France
| | - Yu Fu
- INSERM Unit U981, Gustave Roussy, Villejuif, France
| | | | | | - Ludovic Lacroix
- INSERM Unit U981, Gustave Roussy, Villejuif, France
- Department of Medical Biology and Pathology, Translational research laboratory and biobank, Gustave Roussy, Villejuif, France
| | - Maria Vittoria Dieci
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
- Medical Oncology 2, Veneto Institute of Oncology IOV—IRCCS, Padua, Italy
| | - Maud Kamal
- Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France
| | - Véronique Diéras
- Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France
| | - Anthony Gonçalves
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
| | - Jean-Marc Ferrerro
- Department of Clinical Research, Centre Antoine Lacassagne, Nice, France
| | - Gilles Romieu
- Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France
| | | | | | | | - Fanny Le Du
- Department of Medical Oncology, Centre Eugène Marquis, Rennes, France
| | - Séverine Guiu
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
| | - Florence Dalenc
- Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France
| | | | - Hervé Bonnefoi
- Department of Medical Oncology, Institut Bergonié, Université de Bordeaux, INSERM U916, Bordeaux, France
| | | | - Christophe Le Tourneau
- Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France
- EA7285, Versailles-Saint-Quentin-en-Yvelines University, Montigny-le-Bretonneux, France
| | - Fabrice André
- INSERM Unit U981, Gustave Roussy, Villejuif, France
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
- Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre, France
- * E-mail:
| |
Collapse
|
47
|
Delaloge S, Bonastre J, Borget I, Garbay JR, Fontenay R, Boinon D, Saghatchian M, Mathieu MC, Mazouni C, Rivera S, Uzan C, André F, Dromain C, Boyer B, Pistilli B, Azoulay S, Rimareix F, Bayou EH, Sarfati B, Caron H, Ghouadni A, Leymarie N, Canale S, Mons M, Arfi-Rouche J, Arnedos M, Suciu V, Vielh P, Balleyguier C. The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic. Eur J Cancer 2016; 66:131-7. [PMID: 27569041 DOI: 10.1016/j.ejca.2016.06.021] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2016] [Revised: 05/30/2016] [Accepted: 06/25/2016] [Indexed: 12/16/2022]
Abstract
PURPOSE Rapid diagnosis is a key issue in modern oncology, for which one-stop breast clinics are a model. We aimed to assess the diagnosis accuracy and procedure costs of a large-scale one-stop breast clinic. PATIENTS AND METHODS A total of 10,602 individuals with suspect breast lesions attended the Gustave Roussy's regional one-stop breast clinic between 2004 and 2012. The multidisciplinary clinic uses multimodal imaging together with ultrasonography-guided fine needle aspiration for masses and ultrasonography-guided and stereotactic biopsies as needed. Diagnostic accuracy was assessed by comparing one-stop diagnosis to the consolidated diagnosis obtained after surgery or biopsy or long-term monitoring. The medical cost per patient of the care pathway was assessed from patient-level data collected prospectively. RESULTS Sixty-nine percent of the patients had masses, while 31% had micro-calcifications or other non-mass lesions. In 75% of the cases (87% of masses), an exact diagnosis could be given on the same day. In the base-case analysis (i.e. considering only benign and malignant lesions at one-stop and at consolidated diagnoses), the sensitivity of the one-stop clinic was 98.4%, specificity 99.8%, positive and negative predictive values 99.7% and 99.0%. In the sensitivity analysis (reclassification of suspect, atypical and undetermined lesions), diagnostic sensitivity varied from 90.3% to 98.5% and specificity varied from 94.3% to 99.8%. The mean medical cost per patient of one-stop diagnostic procedure was €420. CONCLUSIONS One-stop breast clinic can provide timely and cost-efficient delivery of highly accurate diagnoses and serve as models of care for multiple settings, including rapid screening-linked diagnosis.
Collapse
Affiliation(s)
- Suzette Delaloge
- Gustave Roussy, Université Paris-Saclay, Department of Medical Oncology, Villejuif, F-94805, France.
| | - Julia Bonastre
- Gustave Roussy, Université Paris-Saclay, Department of Biostatistics, Epidemiology and Health Economics, Villejuif, F-94805, France; INSERM U1018, CESP Centre for Research in Epidemiology and Population Health, Université Paris-Sud, Université Paris-Saclay, Villejuif, France
| | - Isabelle Borget
- Gustave Roussy, Université Paris-Saclay, Department of Biostatistics, Epidemiology and Health Economics, Villejuif, F-94805, France; INSERM U1018, CESP Centre for Research in Epidemiology and Population Health, Université Paris-Sud, Université Paris-Saclay, Villejuif, France
| | - Jean-Rémi Garbay
- Gustave Roussy, Université Paris-Saclay, Department of Surgery, Villejuif, F-94805, France
| | - Rachel Fontenay
- Gustave Roussy, Université Paris-Saclay, Department of Biostatistics, Epidemiology and Health Economics, Villejuif, F-94805, France; INSERM U1018, CESP Centre for Research in Epidemiology and Population Health, Université Paris-Sud, Université Paris-Saclay, Villejuif, France
| | - Diane Boinon
- Gustave Roussy, Université Paris-Saclay, Department of Supportive Care, Villejuif, F-94805, France
| | - Mahasti Saghatchian
- Gustave Roussy, Université Paris-Saclay, Department of Medical Oncology, Villejuif, F-94805, France
| | - Marie-Christine Mathieu
- Gustave Roussy, Université Paris-Saclay, Department of Pathology, Villejuif, F-94805, France
| | - Chafika Mazouni
- Gustave Roussy, Université Paris-Saclay, Department of Surgery, Villejuif, F-94805, France
| | - Sofia Rivera
- Gustave Roussy, Université Paris-Saclay, Department of Radiation Therapy, Villejuif, F-94805, France
| | - Catherine Uzan
- Gustave Roussy, Université Paris-Saclay, Department of Surgery, Villejuif, F-94805, France
| | - Fabrice André
- Gustave Roussy, Université Paris-Saclay, Department of Medical Oncology, Villejuif, F-94805, France
| | - Clarisse Dromain
- Gustave Roussy, Université Paris-Saclay, Department of Radiology, Villejuif, F-94805, France
| | - Bruno Boyer
- Gustave Roussy, Université Paris-Saclay, Department of Radiology, Villejuif, F-94805, France
| | - Barbara Pistilli
- Gustave Roussy, Université Paris-Saclay, Department of Medical Oncology, Villejuif, F-94805, France
| | - Sandy Azoulay
- Gustave Roussy, Université Paris-Saclay, Department of Pathology, Villejuif, F-94805, France
| | - Françoise Rimareix
- Gustave Roussy, Université Paris-Saclay, Department of Surgery, Villejuif, F-94805, France
| | - El-Hadi Bayou
- Gustave Roussy, Université Paris-Saclay, Department of Radiology, Villejuif, F-94805, France
| | - Benjamin Sarfati
- Gustave Roussy, Université Paris-Saclay, Department of Surgery, Villejuif, F-94805, France
| | - Hélène Caron
- Gustave Roussy, Université Paris-Saclay, Department of Medical Oncology, Villejuif, F-94805, France
| | - Amal Ghouadni
- Gustave Roussy, Université Paris-Saclay, Department of Medical Oncology, Villejuif, F-94805, France
| | - Nicolas Leymarie
- Gustave Roussy, Université Paris-Saclay, Department of Surgery, Villejuif, F-94805, France
| | - Sandra Canale
- Gustave Roussy, Université Paris-Saclay, Department of Radiology, Villejuif, F-94805, France
| | - Muriel Mons
- Gustave Roussy, Université Paris-Saclay, Department of Medical Information, Villejuif, F-94805, France
| | - Julia Arfi-Rouche
- Gustave Roussy, Université Paris-Saclay, Department of Radiology, Villejuif, F-94805, France
| | - Monica Arnedos
- Gustave Roussy, Université Paris-Saclay, Department of Medical Oncology, Villejuif, F-94805, France
| | - Voichita Suciu
- Gustave Roussy, Université Paris-Saclay, Department of Pathology, Villejuif, F-94805, France
| | - Philippe Vielh
- Gustave Roussy, Université Paris-Saclay, Department of Pathology, Villejuif, F-94805, France
| | - Corinne Balleyguier
- Gustave Roussy, Université Paris-Saclay, Department of Radiology, Villejuif, F-94805, France
| |
Collapse
|
48
|
Rodriguez C, Suciu V, Poterie A, Lacroix L, Miran I, Boichard A, Delaloge S, Deneuve J, Azoulay S, Mathieu MC, Valent A, Michiels S, Arnedos M, Vielh P. Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients. Mol Oncol 2016; 10:1430-1436. [PMID: 27555543 DOI: 10.1016/j.molonc.2016.07.009] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Revised: 06/13/2016] [Accepted: 07/20/2016] [Indexed: 11/16/2022] Open
Abstract
Determining the status of HER2-neu amplification and overexpression in breast cancer is crucial for prognosis but mostly for treatment purposes. Standard techniques include the determination of IHC in combination with in situ hybridization techniques to confirm a HER2-neu amplification in case of IHC2+ using either a core-needle biopsy or a surgical specimen. qPCR has been also demonstrated to be able to determine HER2 status, mostly in core biopsies or in surgical specimens. Fine-needle aspiration is a reliable, quicker and less invasive technique that is widely used for diagnosis of invasive breast cancer. In this study, we assessed the performance of qPCR in invasive breast carcinomas to determine HER2-neu status by using fine-needle aspiration samples and comparing to standard IHC and FISH. From a total of 154 samples from patients who had nodular breast lesions and attended the 1-day-stop clinic at the Gustave Roussy from March 2013 to October 2014, qPCR was able to determine the HER2 status in a mean of 3.7 days (SD 3.1). The overall concordance with standard HER2-testing was very high: 97% (95% CI 0.94 to 0.99); sensitivity was 96% (0.87-1), specificity 98% (0.95-1) and positive and negative predictive values 88% (0.75-1) and 99% (0.98-1), respectively. In conclusion, our study demonstrates that qPCR performed using fine-needle aspiration samples from a primary tumour is a reliable and fast method to determine HER2/neu status in patients with early breast cancer.
Collapse
Affiliation(s)
- Claudia Rodriguez
- Oncologia Medica, Centro Universitario Contra el Cancer, Universidad Autonoma de Nuevo Leon, Mexico
| | - Voichita Suciu
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France
| | - Audrey Poterie
- Service de Biostatistique et d'Epidémiologie, Gustave Roussy Cancer Campus, Villejuif, France
| | - Ludovic Lacroix
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France; Laboratoire de Recherche Translationnelle et Centre de Ressources Biologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, France
| | - Isabelle Miran
- Laboratoire de Recherche Translationnelle et Centre de Ressources Biologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, France
| | - Amélie Boichard
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France; Laboratoire de Recherche Translationnelle et Centre de Ressources Biologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, France
| | - Suzette Delaloge
- Departement de Médecine, Gustave Roussy Cancer Campus, Villejuif, France
| | - Jacqueline Deneuve
- Service des Opérations de Recherche Clinique, Gustave Roussy Cancer Campus, Villejuif, France
| | - Sandy Azoulay
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France
| | - Marie-Christine Mathieu
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France
| | - Alexander Valent
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France
| | - Stefan Michiels
- Service de Biostatistique et d'Epidémiologie, Gustave Roussy Cancer Campus, Villejuif, France; INSERM U1018, CESP, Université Paris-Sud, Université Paris-Saclay, Villejuif, France
| | - Monica Arnedos
- Departement de Médecine, Gustave Roussy Cancer Campus, Villejuif, France; INSERM U981 et Université Paris-Sud, Université Paris-Saclay, Villejuif, France
| | - Philippe Vielh
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France; Laboratoire de Recherche Translationnelle et Centre de Ressources Biologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, France.
| |
Collapse
|
49
|
Arnedos M, Cheaib B, Bayar MA, Michiels S, Scott V, Adam J, Leroux-Kozal V, Marty V, Mazouni C, Sarfati B, Bieche I, Gentien D, Delaloge S, Lacroix-Triki M, Andre F. Abstract CT041: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial. Clin Trials 2016. [DOI: 10.1158/1538-7445.am2016-ct041] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
50
|
Kamal M, Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria JC, Massard C, Levy C, Arnedos M, Garrabey J, Boursin Y, Deloger M, Fu Y, Commo F, Scott V, Lacroix L, Martin E, Dieras V, Goncalves A, Ferrero JM, Romieu G, Vanlemmens L, Mouret-Reynier MA, Thery JC, Kerbrat P, Guiu S, Dalenc F, Clapisson G, Bonnefoi H, Jimenez M, Le Tourneau C, Andre F. Abstract LB-353: Mutational profile of metastatic breast cancers using whole-exome sequencing: a retrospective analysis of 216 samples from SAFIR01 / 02 / SHIVA / MOSCATO trials. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-lb-353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Major advances have been achieved in the understanding of breast cancer biology using high throughput technologies at the DNA and RNA levels. Most of these advances were made in early breast cancers (eBC) which are cured in about 80% of the cases. Nevertheless, little is known about metastatic breast cancers (mBC) which remain lethal in most of the cases.
Methods: Whole-exome sequencing was performed on 216 tumour-normal pairs from mBC patients who underwent a biopsy in the context of the SAFIR01/SAFIR02/SHIVA or MOSCATO prospective trials. TCGA dataset (n = 772) was used to assess frequency of mutations in eBC.
Findings: Twelve genes (TP53, PIK3CA, GATA3, ESR1, MAP3K1, CDH1, AKT1, MAP2K4, RB1, PTEN, CBFB, CDKN2A) were identified as drivers using MutSig algorithm (FDR<0.1). Eight genes (ESR1, FSIP2, FRAS1, OSBPL3, EDC4, PALB2, IGFN1, AGRN) were more frequently mutated in mBC as compared to eBC (TCGA, FDR<0.01). HR+/Her2- mBC presented a high prevalence (6.3%) of mutations on genes located on mTOR pathway (TSC1, TSC2) as compared to HR+/Her2- eBC (0.7%, p = 0.0004). A subset of HR+/Her2- mBC (n = 17, 12%) presented a high mutational load (>150 non-synonymous mutations). This subset was observed in 2% of early breast cancers (TCGA, p = 7.1e?06). The prevalence of this subset increased with the time from diagnosis of metastasis to biopsy. Highly mutated HR+/Her2- mBC (n = 17) presented higher rate of PIK3CA mutations (n = 12, 70%), high number of neoantigens, an APOBEC mutational signature and a poor outcome (multivariate analysis, HR = 4.68, 95%CI: 1.8-12.1, p = 0.001).
Interpretation: Whole exome sequencing of metastatic breast cancers identifies a subset of HR+/Her2- mBC who present a high mutational load. RB1, PALB2 and TSC1/2 mutations were found enriched in either mBC or HR+ mBC.
Fundings: Breast Cancer Research Foundation, Fondation ARC, Fondation Lombard-Odier “Philanthropia”, Odyssea, Operation Parrains Chercheurs, Dassault Foundation, French NCI: INCa-DGOS-INSERM 6043
Citation Format: Maud Kamal, Celine Lefebvre, Thomas Bachelot, Thomas Filleron, Marion Pedrero, Mario Campone, Jean-Charles Soria, Christophe Massard, Christelle Levy, Monica Arnedos, Julie Garrabey, Yannick Boursin, Marc Deloger, Yu Fu, Frederic Commo, Veronique Scott, Ludovic Lacroix, Emmanuel Martin, Veronique Dieras, Anthony Goncalves, Jean-Marc Ferrero, Gilles Romieu, Laurence Vanlemmens, Marie-Ange Mouret-Reynier, Jean-christophe Thery, Pierre Kerbrat, Severine Guiu, Florence Dalenc, Gilles Clapisson, Hervé Bonnefoi, Martha Jimenez, Christophe Le Tourneau, Fabrice Andre. Mutational profile of metastatic breast cancers using whole-exome sequencing: a retrospective analysis of 216 samples from SAFIR01 / 02 / SHIVA / MOSCATO trials. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr LB-353.
Collapse
Affiliation(s)
| | | | | | | | | | - Mario Campone
- 5Institut de Cancérologie de l’Ouest, Nantes, France
| | | | | | | | | | | | | | | | - Yu Fu
- 2Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | - Gilles Romieu
- 11Institut du Cancer de Montpellier, Montpellier, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|